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Introduction 
1. Definition and prevalence of GTD 
Gestational trophoblastic disease (GTD) consists of a spectrum of interrelated conditions arising 
from the placenta [1].The malignant form is known as gestational trophoblastic neoplasia (GTN) 
and trophoblastic tumor. Histologically, GTD is classified into benign forms of complete and partial 
hydatidiform moles and malignant forms of invasive moles, gestational choriocarcinoma, rare 
placental site trophoblastic tumors (PSTT), and epithelioid trophoblastic tumor (ETT) [2]. The 
incidence of GTD differs according to the geographic location, which has been attributed, at least in 
part, to racial or ethnic differences [3]. The reported incidences are 1/125 live-births in Taiwan, 
2/1000 pregnancies in Japan and South East Asia, 1/1500 in United States, and 1/1000 in Europe 
[4]. 
2. Hydatidiform mole 
2.1. Pathogenesis of molar pregnancy 
Molar pregnancies are subdivided histopathologically and genetically into complete mole (CM) and 
partial mole (PM). CMs are without evidence of fetal tissue—diploid and from androgenic origin. 
Up to 80% of CMs arise from the fertilization of an ovum by a single sperm where the sperm 
duplicates after fertilization, whereas 20%–25% of CMs arise from fertilization of an ovum by two 
different sperms [1]. Of PMs, 90% are triploid in origin with one set of maternal haploid genes and 
two sets of paternal haploid genes. In most cases, PMs occur succeeding dispermic fertilization of 
an ovum; 10% PMs are tetraploid or mosaic in origin. In case of PMs, there is evidence of fetal 
tissue or fetal red blood cells [5]. Theca Lutein cysts may be present in 20%–40% of patients with 
CMs [6]. Malignant sequel occurs in 20% and <5% of patients with CMs and PMs, respectively [7]. 
Immunostaining with P57 is an established method to distinguish between CMs and PMs and non-
molar pregnancies [8]. P57 is expressed exclusively by maternal chromosomes so that 
immunostaining is negative in CMs and positive in PMs and non-molar pregnancies [9]. 
2.2. Human chorionic gonadotropin 
GTD produces human chorionic gonadotropin (hCG) is a disease-specific tumor marker. It is easily 
measured quantitatively in urine and blood, and its level corresponds with the disease severity. hCG 
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is a placental glycoprotein comprising two dissimilar subunits: α-subunit resembling that of the 
pituitary glycoprotein hormones and β-subunit that is unique to placental production. hCG exists in 
many forms, including at least six crucial variants, which are detected in serum, as follows: 
hyperglycosylated, nicked, absent C-terminal of β subunit, free β subunit, nicked free β subunit, and 
free α subunit. In GTD, hCG molecules differ from those in normal pregnancy; they are more 
heterogeneous and degraded in GTD. Considering this, an assay that can recognize all main forms 
of hCG and its multiple fragments should be used for following up on patients with GTD [10]. 
Nowadays, majority of institutions perform rapid automated radiolabeled monoclonal antibody 
sandwich assays measuring distinct mixtures of hCG-related molecules [11]. GTD is usually 
accompanied with markedly elevated hCG values higher than those during normal pregnancy. 
Nearly 50% patients with CMs have pre-evacuation hCG levels >100,000 mIU/mL [12]. 
2.3. Diagnosis of molar pregnancy 
Typically, GTD is diagnosed during first trimester. The most common symptom of complete 
hydatidiform mole (CHM) is vaginal bleeding, whereas other symptoms include hyperemesis 
gravidarum, uterine enlargement more than the expected gestational age, absence of fetal heart 
tones, high values of hCG compared with gestational age, and pregnancy-induced hypertension 
[13]. 
Nearly 40%–60% of complete and partial molar pregnancies are detected by transvaginal 
ultrasound. However, histologically, 10% of suspected molar pregnancies based on ultrasonography 
appear to be non-molar hydropic abortions [14]. Therefore, histological examination of any material 
related to non-viable pregnancy should be performed [15]. Recently, a CM has been progressively 
diagnosed; however, to our knowledge, CM has not been reported to be associated with change in 
the development of GTN [16]. 
2.4. Treatment of molar pregnancy 
Molar pregnancy is treated by suction evacuation under general anesthesia, but local or regional 
anesthesia can also be used. Suction evacuation is performed after serial Hegar dilatation of the 
uterine cervix [17]. Ultrasound guidance facilitates complete evacuation of the uterus. Intravenous 
oxytocin is used after the dilatation of the cervix and should be continued for several hours 
postoperatively to reduce uterine bleeding. Anti-D immunoglobulin should be administrated for Rh-
negative patients after evacuation, although fetal red blood cells should not be present in a CM due 
to the expression of Rhesus D factor on trophoblast [18]. Trophoblastic embolization may occur 
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after molar evacuation, which is the main cause of respiratory distress. There are also other different 
causes, such as anemia, hyperthyroidism, and iatrogenic fluid overload [19]. 
2.5. Monitoring and contraception 
Following evacuation, it is mandatory to monitor all patients to diagnose and treat malignant sequel. 
Serial consecutive quantitative serum hCG levels should be performed. It is preferred to do so in a 
single laboratory using the same measurement kit. Ideally, serum hCG levels should be evaluated 
after 48 hours of evacuation, every 1–2 weeks while elevated, and at monthly intervals for 
subsequent 6 months. Patients who require over 56 days to reach normal hCG value have ten-fold 
increased risk of developing GTN after hCG normalization [20]. Regression curves have been 
designed to determine the pattern of hCG during follow-up [21]. 
The Dutch guidelines recommend no further follow up after first establishing a normal value of 
hCG [22]. Moreover, the data of a recent meta-analysis supports decreasing hCG monitoring from 
six to three months postnormalization in CM and performing only one confirmatory check after a 
month in PM [23]. 
Hormonal contraception is recommended while monitoring hCG values. Reported studies support 
using hormonal contraception as it does not intensify risk of post-molar GTN or delayed hCG 
normalization [24]. Contraception is allowed in Islamic laws for the sake of mother’s health and 
welfare. 
Pregnancies following molar evacuation (after 6 months of contraception) are usually normal, 
although pregnancies conceal the value of monitoring hCG levels, which may result in a delayed 
diagnosis of post-molar malignancy [25]. 
2.6. Prophylactic chemotherapy  
Prophylactic chemotherapy decreases the risk of progression to GTN in women with CMs who are 
at a high risk of malignant transformation; however, currently, there is limited evidence supporting 
prophylactic chemotherapy due to poor methodological quality and small size of included studies. 
As prophylactic chemotherapy may increase drug resistance, delay treatment of GTN, and expose 
women to toxic side effects, this practice should not to be recommended unless in a prospective 
study [26]. Additionally, the chemotherapy does not eradicate the need for post-evacuation follow-
up. 
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2.7. Diagnosis of post-molar GTN 
Diagnosis of GTN includes an increase in hCG levels after evacuation of HMs and/or histologically 
diagnosed as gestational choriocarcinoma or invasive mole, ETT, or PSTT; it resents clinical or 
radiological evidence of metastasis. To diagnose post-molar GTD, different modalities of hCG-
interpreting criteria have been conducted. The international federation of gynecologist and 
obstetricians (FIGO) standardized hCG criteria for this purpose [27]. The following criteria were 
submitted by FIGO: 
1- An hCG level plateau of 3 values plus or minus 10% recorded over 3-week duration (days 1, 7, 
and 21). 
2- An hCG level rise >10% of 3 values recorded over 2-week duration (days 1, 7, and 14). 
3- Persistence of detectable hCG for >6 months after molar evacuation. 
The Charing Cross Trophoblastic Disease Center (London, United Kingdom) recommends 
immediate start of chemotherapy in case serum hCG concentration is ≥20000 mIU/Ml after four or 
more weeks of uterine evacuation, considering the increased chance of developing GTN in such 
patients. This recommendation was adopted by the European Organisation for the Treatment of 
Trophoblastic Disease (EOTTD) and many countries worldwide. However, this recommendation 
has not been adopted by FIGO [20]. 
2.8. Recurrent HM 
Recurrent HM (RHM) is described as the occurrence of at least two HMs in the same patient. Fifty 
to eighty percent of patients with RHMs have bi-allelic pathogenic variants in NLRP7 or KHDC3L. 
However, not all genotypic types of the moles are yet identified [28]. 
3. Gestational trophoblastic neoplasia (GTN) 
3.1. Classification 
Table 1 represents a revised FIGO scoring system including various patient characteristics that 
affect the response to chemotherapy. The following factors contribute to determining FIGO 
prognostic score: patient’s age, previous pregnancy, duration of disease, pretreatment hCG level, 
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site and number of metastases, size of the largest tumor, and exposure to prior chemotherapy [2]. 
However, histopathologic diagnosis is not included as a factor. 
Each item is scored 0–4; after sum of these risk scores; ≤6 is defined as low-risk factor, whereas ≥7 
is high-risk [27]. Moreover, corresponding to a combined anatomic staging and scoring system, 
FIGO defines low-risk GTN as non-metastatic (stage I) and metastatic (stages II and III) disease 
with a prognostic score of <7. Nevertheless, FIGO stage IV—or any stage with a World Health 
Organization (WHO) score of >7—indicates high risk of resistance to single-agent chemotherapy, 
elevated risk of recurrence, and the necessity for combination chemotherapy to get the best outcome 
[29]. 
Table 1. Revised FIGO Scoring System [27] 
FIGO Score 0 1 2 4 
Age ≤39 >39 — — 
Antecedent Pregnancy Hydatidiform 
mole 
Abortion Term pregnancy — 
Interval from index pregnancy 
(months) 
<4 4—6 7—12 >12 
Pretreatment hCG level 
(mIU/mL) 
<1,000 1,000—
10,000 
>10,000—100,000 >100,000 
Largest tumor size including 
uterus (cm) 
3—4 5 — — 
Site of metastasis Lung, vagina Spleen, 
kidney 
Gastrointestinal 
tract 
Brain, liver 
Number of metastasis 
identified 
0 1—4 4—8 >8 
Previous failed chemotherapy — — Single drug 2 or more 
drugs 
 
GTN is highly responsive to chemotherapy. Low-risk GTN can be cured with single-agent 
chemotherapy with either methotrexate (MTX) or actinomycin-D (Act-D) in 90% of cases; multi-
agent chemotherapy is required in 10% [30]. For patients with high-risk GTN, multi-agent 
chemotherapy is the primary treatment of choice [31]. Worldwide, the most commonly used 
regimen for such patients comprise etoposide, MTX, Act-D, cyclophosphamide, and vincristine 
(EMA/CO combination) [32]. 
Ch. 1 │ Introduction and Overview: objectives and outline of the thesis. 
 
6 
It has been reported that high hCG levels [33], presence of metastatic disease [34], CM [30], high-
risk FIGO score [35], increasing neo-angiogenesis [36], and patients aged above 40 years [37] are 
associated with increased risk of initial chemotherapy resistance and long time to achieving 
remission in low-risk GTN patients. 
In treating PSTT and ETT, the FIGO score has no rule because single-agent chemotherapy should 
not to be the first therapeutic choice for these rare tumors [38].  
Adjuvant surgical treatment of GTN can be implemented to decrease tumor load in the uterus at the 
start of treatment; this leads to reduced need for chemotherapy when future pregnancy is no longer 
desired, control tumor hemorrhage, and/or remove resistant/persistent disease in the uterus or at 
metastatic sites [39]. While treating ETT and PSTT, surgical intervention is mainstay as these 
tumors are often limited to the uterus and less sensitive to chemotherapy [40]. 
3.2 Clinical and pathologic considerations 
The clinical presentation of post-molar GTN is far more essential than the histologic or radiological 
evidence in determining its management and prognosis [41]. The term invasive mole describes the 
disease confined to the uterus and is characterized by the presence of edematous chorionic villi with 
trophoblastic proliferation that invades the myometrium. Majority of patients are clinically 
diagnosed and not confirmed histologically. Dilatation and curettage should be avoided to prevent 
morbidity or mortality caused by uterine perforation of the soft uterus during the procedure [42]. 
Gestational choriocarcinoma develops early distant metastasis in the vagina, lung, liver, and brain; 
thus, chemotherapy should be started in a well-timed manner to avoid bleeding complications at 
metastatic sites [43]. PSTT is characterized by the absence of villi and presence of intermediate 
trophoblastic cells [40]. The number of syncytiotrophoblastic cells is less in PSTTs, with 
subsequently decreased levels of secreted hCG. Additionally, PSTTs are lesser sensitive to 
chemotherapy than other types of malignant GT cells [44]. 
Most PSTTs follow non-molar gestations. PSTTs often exhibit diffused immunostaining with 
intermediate trophoblastic markers, such as human placental lactogen and Ki67 [45]. ETT is a rare 
variant of PSTT that simulates carcinoma. Depending on morphologic and histochemical aspects, 
ETT develops from the neoplastic transformation of chorionic-type intermediate trophoblasts. 
Majority of the cases occur many years after a full-term delivery [46]. Both PSTT and ETT produce 
low levels of hCG. 
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3.3 Management of GTN 
As soon as the diagnosis of malignant GTD is suspected, metastasis should be evaluated. Besides 
history and physical examinations, the following laboratory studies should be performed: blood 
type and antibody screen, complete blood count, clotting studies, liver and renal studies, and the 
determination of pre-therapy hCG level. The following radiographic studies are recommended: 
chest X-ray or computed tomography (CT) scan of the chest and pelvic ultrasonography. Rarely, 
MRI scan or abdominopelvic CT with contrast is recommended. CT scan of the brain is needed in 
symptomatic patients or in cases of pulmonary metastasis [27,47]. The role of positron emission 
tomography (PET) in evaluating metastatic GTN has not yet been well established. The available 
information suggests that PET does not add value to GTN staging, whereas conventional imaging 
work-up is lesser expensive and more widely available than PET [6]. 
Management of low-risk non-metastatic GTN 
Generally, low-risk (LR) non-metastatic GTN is treated with single-agent chemotherapy using 
either MTX or Act-D. There are different MTX regimens used as initial treatment for patients with 
LR (50 mg fixed dose, 50 mg/m2 of body surface area, or 1 mg/kg of body weight on days 1, 3, 5, 
and 7, with or without folinic acid rescue, 0.4 mg/kg on days 1–5, and 30–50 mg/m2 once weekly). 
There are also different Act-D regimens used, including 10–13 mcg/kg on days 1–5 and 1.25 
mg/m2 biweekly. This makes it difficult, with the data available, to actually evaluate the best initial 
treatment for low-risk GTN [48]. MTX is excreted entirely by the kidneys and can result in hepatic 
toxicity; thus, patients should test their normal renal and liver functions before each treatment. 
Hematologic indices should be carefully monitored during chemotherapy. 
According to the updated Cochrane systematic review [48], Act-D is more likely to achieve primary 
cure in women with low-risk GTN and less likely to result in treatment failure than MTX regimen. 
However, Act-D is associated with greater risk of severe adverse events and costlier than MTX 
regimen. 
Chemotherapy should be continued until normal hCG levels are achieved, consequently additional 
two courses should be administrated after the first normal hCG value record. However, after a 
retrospective analysis of LR patients treated in the Netherlands and UK, Lybol et al. [49] concluded 
that three courses of consolidation chemotherapy are better than two in treating low-risk GTN to 
decrease the risk of disease relapse. 
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In selected cases, a hysterectomy is an effective way to decrease or eliminate tumor bulk. As a first 
line of management, hysterectomy should be considered in older patients with localized disease and 
no desire to preserve fertility and those presenting with chemotherapy resistance. For patients with 
widespread distant metastasis, the value of hysterectomy exists in removal of chemotherapy-
resistant tumor bulk with favorable effect on survival [50]. After hysterectomy, chemotherapy is 
mandatory in women with metastasis until normal hCG levels are achieved. 
Second uterine curettage 
The role of second uterine curettage as a single or additional treatment in the management of 
postmolar GTN is unclear. Previous retrospective studies have found widely differing cure rates 
varying 9%–80% [51,52]. A debulking effect of second uterine curettage has been reported by two 
retrospective analyses that reported that few chemotherapy courses were required to reach 
undetectable serum hCG levels after second curettage [51,53]. This reduction is related to serum 
hCG level and the presence or absence of myometrial invasion and distant metastases. 
Recently, two prospective observational studies were published. First, a small prospective pilot 
study reported cure in 10 of 12 patients after second curettage in post-molar GTN [54]. The second 
study, performed by the Gynecologic Oncology Group, reported cure rates of 40% for low-risk non-
metastatic GTN using second uterine curettage as a single treatment [55]. The disadvantages of 
second uterine curettage include complications such as uterine perforation, infection and bleeding, 
and delay in starting chemotherapy when post-curettage hCG levels fail to normalize [51,55]. 
Second curettage is not recommended by The American College of Obstetricians and Gynecologists 
because it does not often result in the remission of hCG levels or offer help in the management of 
GTN; however, it can result in uterine perforation and hemorrhage [42]. 
Management of low-risk metastatic GTN 
Women with FIGO risk score <7, metastatic disease, and any high-risk clinical factors are still 
considered to have a low-risk disease. 
Treatment can be successfully achieved with initial single-agent regimens. This therapy is often 
continued for 5 days of MTX treatment or intravenous actinomycin-D recycled at 14-day interval. 
Most patients with low-risk metastatic GTD can be cured using conventional single-agent 
chemotherapy [56]. Hysterectomy, in additional to chemotherapy, decreases the amount of 
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chemotherapy needed to achieve remission in these patients [31]. Similar to the treatment of non-
metastatic GTD, two cycles of chemotherapy should be given after the first normal hCG value. The 
overall complete remission rate is up to 100% [56]. 
Management of high risk metastatic GTN 
Patients with FIGO risk score of 7 or more are considered to have a high-risk disease. They require 
multi-agent chemotherapy. Surgery and/or radiation are often incorporated in the treatment [57]. 
Aggressive treatment by multi-agent chemotherapy for these women is an integral part of the 
management. Nearly 25% patients with high-risk metastatic GTN have refractory disease, relapse, 
or extensive metastatic disease (FIGO stage IV, score > 12) and require recognition of 
chemotherapy-resistant sites for surgical resection, central nervous system irradiation, and/or 
alternate therapeutic regimens. The most commonly used chemotherapeutic regimens include 
EMA/CO, EMA-EP (etoposide, MTX, Act-D, etoposide, cisplatin), and TE/TP (paclitaxel, 
etoposide, paclitaxel, cisplatin), which results in 75%–80% response rate [58]. 
Regarding ultra-high risk group defined as FIGO score >12; patients should immediately be 
referred to a GTD Centre. Imaging should be performed if not recently done (contrast CT-
chest/abdomen, MRI brain, MRI pelvis). Low-dose induction EP for 1-3 cycles should be 
considered depending on the clinical condition followed by EP/ EMA or EMA/CO. After 
normalization, consolidation courses should be given for 8 weeks according to local GTD Centre 
advice [59]. 
The management of brain metastasis is controversial. Radiation therapy is concurrently used with 
chemotherapy to limit acute hemorrhagic complications occurring from these metastases. Systemic 
chemotherapy combined with brain irradiation is successful in controlling brain metastasis, with 
cure rates up to 75% [60]; intrathecal MTX infusion without brain irradiation has similar remission 
rates [61]. 
In the hope of eradication of all viable tumors, chemotherapy should be continued till hCG values 
normalize, followed by at least 2–3 courses of maintenance chemotherapy. 
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3.4 Follow-up 
Following the remission of hCG values, patients with malignant GTD should undergo serial testing 
of hCG levels at 2-week intervals for the first 3 months of remission and after that at 1-month 
intervals for 1 year. 
In the follow-up of GTN, most relapses are noted to occur within the first 12 months after 
completion of chemotherapy; biannual measurement of β-hCG for 5 years is usually sufficient [20]. 
3.5 Fertility after treatment of GTN 
Most patients with GTN are in reproductive age group, and preserving fertility is an important issue 
to them. Chemotherapy can affect ovarian function, and the extent of gonadotoxic effect depends on 
the type of chemotherapy, dose and schedule of treatment, and patient’s age [62]. Major concerns 
related to chemotherapy are possible infertility, risk of premature ovarian failure, and the mutagenic 
and teratogenic effects of chemotherapy that can affect subsequent pregnancy outcomes. 
The psychological effects of GTN should be considered, especially in younger patients; questions 
about infertility and premature menopause increase distress and decrease patient compliance in 
follow-up [63]. Nevertheless, the obstetric outcomes of those who conceive after chemotherapy are 
similar to those of the general population, but patients should be advised not to get pregnant for at 
least the next 1 year to avoid any misinterpretation of hCG results and possible harmful effects of 
chemotherapy on the ovaries and fetal outcome. Nonetheless, if patients conceive within that 1 year, 
they can be reassured that overall outcome is favorable and there is no need to terminate pregnancy 
[64]. 
4. Objectives and outline of the thesis 
This thesis aims to investigate several aspects of the diagnosis and treatment of GTN with special 
focus on the effect of second uterine curettage on the number of chemotherapy courses required to 
achieve hCG normalization. 
Chapter 1 presents a general introduction that aims to provide literature review regarding 
classification, diagnosis, and modalities of the treatment of GTD. The chapter ends with objectives 
of the thesis. In chapter 2, we investigated incidence, prognosis, and outcome of GTD in Lower 
Egypt. Until now, the data of incidence and outcome of GTD in Egypt were scarce, which may be 
due to poor registration of cases. We conducted a prospective 1-year study aimed to address the 
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incidence and outcome of GTD at Mansoura University Hospital, which serves most of patients 
from Lower Egypt after the development of specialized GTD clinic with a strict registration system. 
So far, globally, no consensus guidelines are available for treating GTN in patients who are ≥ 40 
years old. Treatment of such cases depends mainly on expert opinions. In chapter 3, we performed a 
multi-center retrospective analysis on the clinical outcomes of different treatment strategies in 
patients aged 40 years or above. For this, we analyzed the data retrieved from five centers in five 
countries. 
Subsequently, we aimed to investigate the effect of second uterine curettage on the number of 
chemotherapy courses needed to achieve hCG normalization in low-risk GTN patients. We 
performed a single-center randomized phase II trial in patients with low-risk post-molar GTN to 
evaluate the impact of second curettage on the number of chemotherapy courses, need of second-
line chemotherapy, relapse rate, and complications, results of which are presented in chapter 4. 
It is crucial for us to share our experience of performing this randomized study. In chapter 5, our 
considerations have been mentioned. We address benefits and obstacles of collaboration between 
Western and non-Western countries in conducting high-quality scientific researches. 
We explored the reproductive outcomes achieved after fertility-preserving treatment of 
premalignant and malignant gynecologic tumors, including GTN. GTN usually occurs in 
reproductive age where the fertility of patient is keened by family and physician. As described in 
chapter 6, a retrospective study was conducted to find the reproductive outcomes after treatment of 
premalignant and early gynecologic malignancies, including 34 cases of GTN. 
We investigated the prevalence of GTD after histopathologic examination of specimens of 
pregnancy termination and post-abortive bleeding. We hypothesized that some cases of GTD were 
misdiagnosed as miscarriage on clinical basis, and the diagnosis of GTD has been settled only after 
histopathologic examination. In chapter 7, we conducted histopathological review of 640 specimens 
of contents of uterine evacuation after pregnancy termination and post-abortive bleeding. 
We planned to determine the most specific histopathological and immunohistochemical features 
required for accurate diagnosis that can reliably predict the clinical behavior of molar pregnancy as 
presented in chapter 8. Although the morphological characteristics of products of conception 
specimens, including molar pregnancies, are well described, substantial histopathological 
similarities are observed between different entities, especially in cases of early pregnancies. 
Furthermore, to our knowledge, there are no criteria for predicting cases with progression to 
persistent GTD. 
We investigated the mutational status in a patient with six recurrent molar pregnancies who was 
managed in the GTD clinic of Mansoura University. NLRP7 sequencing was performed, and 
mutation analysis revealed a novel mutation in NLRP7 as described in chapter 9. 
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Chapter 10 presents the general discussion of different studies presented in this thesis and their 
impact on the decision of the management of patients with low-risk GTN and future perspectives. 
Chapter 11 presents the summary of the thesis in English, Dutch, and Arabic languages. 
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Abstract 
Background. Gestational trophoblastic disease (GTD) defines a spectrum of proliferative disorders of 
trophoblastic epithelium of the placenta. Incidence, risk factors, and outcome may differ from a country to 
another. 
 Objective. To describe incidence, patients, characteristics, treatment modalities, and outcome of GTD at 
Mansoura University which is a referral center of Lower Egypt.  
Methods. An observational prospective study was conducted at the GTD Clinic of Mansoura University. 
The patients were recruited for 12 months from September 2015 to August 2016. The patients’ 
characteristics, management, and outcome were reported.  
Results. We reported 71 clinically diagnosed GTD cases, 62 of them were histologically confirmed, 58 
molar (33 CM and 25 PM) in addition to 4 initially presented GTN cases. Mean age of the studied cases was 
26.22 years ± 9.30SD. Mean pre-evacuation hCG was 136170 m.i.u/ml ±175880 SD. Most of the cases 
diagnosed accidentally after abnormal sonographic findings (53.2%). Rate of progression of CM and PM to 
GTN was 24.2% and 8%, respectively. 
Conclusion.The incidence of molar pregnancy and GTN in our locality was estimated to be 13.1 and 3.2 per 
1000 live births respectively. We found no significance between CM and PM regarding hCG level, time to 
hCG normalization, and progression rate to GTN. 
Key words. Molar pregnancy; incidence; outcome. 
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Introduction 
Gestational trophoblastic disease (GTD) defines a spectrum of proliferative disorders of 
trophoblastic epithelium of the placenta [1]. GTD was classified histologically into benign forms of 
complete and partial hydatidiform moles and malignant forms of invasive moles, gestational 
choriocarcinoma, placental site trophpoblastic tumors (PSTT), and epithelioid trophoblastic tumors 
[2]. The incidence of gestational trophoblastic disease differs according to geographic distribution. 
The highest reported incidence was 1/125 live births in Taiwan, while 2/1000 pregnancies in Japan 
and South East Asia, 1/1500 in United States and 1/1000 in Europe [3]. However, underestimation 
of the molar pregnancy incidence may occur if the products of conception are not routinely 
subjected to histological examination and if the registry system is not developed [4]. Risk factors of 
molar pregnancy include genetic, racial [5], extremes of maternal age [6,7], dietary and nutritional 
factors [8].  
Hydatidiform moles typically are diagnosed during the first trimester [9]. Abnormal vaginal 
bleeding is the commonest symptom. Other signs and symptoms include hyperemesis gravidarum, 
oversized uterus, absent fetal heart pulsations, pregnancy induced hypertension and abnormally 
high levels of hCG [10]. By ultrasound, molar tissue is usually identified as a diffuse mixed 
echogenic pattern replacing the placenta (snowstorm), produced by villi with intervening 
intrauterine blood clots [11]. Treatment of molar pregnancy is by suction evacuation with a soft 
plastic cannula [12] with ultrasound control. Following evacuation, it is mandatory to monitor all 
patients to diagnose and treat malignant progression.   
Post-molar GTN is typically diagnosed in patients with serum B-hCG raised, plateau, or persistent 
beyond 6 months of molar evacuation [13].  GTN are categorized into low or high risk according to 
the International Federation of Gynaecology and Obstetrics (FIGO) staging and modified World 
Health Organization (WHO) risk-factor scoring system [14]. Patients with FIGO stages I–III with a 
score of 0–6 are categorized as low-risk GTN while either FIGO stage IV or any stage with WHO 
score ≥7 are classified as high risk [15]. GTN is well known to be highly responsive to 
chemotherapy. Low-risk GTN is cured with single-agent chemotherapy with either methotrexate or 
actinomycin-D in 90% of the cases [16]. High-risk GTN is treated with combination chemotherapy 
to optimize outcome [17,18].  
Since the incidence, patients, characteristics, treatment modalities, and outcome of gestational 
trophoblastic disease may differ from country to another; we conducted this prospective study to 
describe our early experience in Gestational Trophoblastic Clinic, Mansoura University, Egypt.  
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Methods 
An observational prospective study was conducted at the GTD Clinic of Mansoura University 
Hospitals, Mansoura, Egypt. Mansoura University Hospital provides tertiary healthcare for most of 
the Delta region of Egypt, with a population of about 12 millions. The patients were recruited for 12 
months (from September 2015 to August 2016), followed by 6 months so that the follow up was at 
least 6 months for all patients.  
Participants 
Inclusion criteria: 
 The current study included both molar pregnancies and GTN. Molar pregnancies were diagnosed 
clinically and based on ultrasound criteria with an abnormally high hCG levels. Patients presented 
by gestational trophoblastic neoplasia included postmolar GTN (with serum β-hCG raised, plateau, 
or persistent    beyond    6 months of molar evacuation) or cases with histological evidence of 
choriocarcinoma, invasive mole, PSTT, and epithelioid trophoblastic tumors. 
Exclusion criteria: 
Histologic confirmation of “products of conception” after suction evacuation and patients who 
refused to participate in the study. 
Collected patient variables included the age, the body mass index, parity, gestational age, uterine 
size in weeks, sonographic findings, serum β-hCG, lung metastasis, and medical diseases were 
recorded. To get a rough estimate of prevalence of GTD in our Hospital; the included cases were 
compared to the whole number of live births in Mansoura University Hospitals. 
Treatment of molar pregnancy:   
1. Pre-operative preparation: routine laboratory tests, β-hCG, chest X-ray and anaesthetic 
consultation were performed.  
2. The patients were treated by suction evacuation using a soft plastic cannula, guided by 
ultrasonography under short acting general anaesthesia. After dilation of the cervix; Oxytocin 5 IU 
ampoule (Syntocinon, Novartis, Egypt) was given in 500 ml saline infusion in case of severe uterine 
bleeding during suction evacuation. After the procedure was completed; Ergometrine 0.2 mg 
ampoule (Methergine, Novartis, Egypt) was given intramuscular to reduce uterine bleeding. 
Prophylactic broad spectrum antibiotic was given. The patient was discharged 48 hours after 
evacuation. 
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3. Follow up. The patients were followed by serum β-hCG weakly till 3 negative results (below the 
reference range of 5 mIU/mL). Subsequently, hCG was checked monthly for 6 months to insure that 
the hCG levels remained undetectable. During the post evacuation management, the patients were 
under the umbrella of contraception; preferably combined oral contraception pills.  
Diagnosis, staging, and risk factors for gestational trophoblastic neoplasia: 
Progression to GTN was diagnosed using the FIGO, 2002 criterion [15]: hCG levels rising (more 
than 10%) for three consecutive weeks, plateaued for four weeks or persistent beyond 6 months. 
Patients with a histological diagnosis of any of the malignant forms or metastases detected during 
post-molar follow-up were also classified as GTN cases. GTN was staged according to the FIGO, 
2002 criteria and classified into low or high risk according to modified WHO scoring system. The 
diagnosed cases as GTN were discussed in the tumor board meetings to receive chemotherapy and 
possibility of surgical interference. 
Ethical considerations. 
Oral and written consent was taken from the patients. The study was approved by the institutional 
review board (IRB) of Faculty of Medicine, Mansoura University (number: MS/16.01.01). 
Statistical analysis  
Data were analyzed with SPSS version 21. The normality of data was first tested with one-sample 
Kolmogorov-Smirnov test. Qualitative data were described using number and percent. Association 
between categorical variables was tested using Chi-square and Fischer exact tests. Continuous 
variables were presented as mean ± SD (standard deviation) for parametric data and median (Min-
Max) for non-parametric data. The two groups were compared with Student t test for parametric 
data and Mann Whitney test for non-parametric data. P values were considered statistically 
significant when p < 0.05. 
Results 
Between 1st of September 2015 till the 31st of August 2016, 71 clinically diagnosed patients as GTD 
were included in the study. Sixty-two were confirmed histologically to have GTD (58 cases of 
molar pregnancy and 4 cases of GTN). The total number of life births in MUH during the same 
period was 4398 thus the incidence of molar pregnancy and GTN in MUH is estimated to be 13.1 
and 3.2 per 1000 live births respectively. In the same period of time, the number of live births in 
Dakahlia governorate was 155,962 representing a population-based incidence of molar pregnancy 
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and GTN 0.37 and 0.09 per 1000 live birth respectively. The mean age of the cases with molar 
pregnancy was 26.22 ± 9.30 years with 16.1% of the cases are less than 18 years old and 12.9% are 
40 years old or more. We reported one case with familial recurrent hydatidiform moles where CM 
was diagnosed in her 2 sisters. Genetic study was done for the sisters and revealed a mutation of 
NLRP7.Other sociodemographic criteria were shown in table (1). The clinical presentation of the 
studied cases is demonstrated in table (2), as can be noticed; thirty-three cases (53.2%) were 
accidentally diagnosed by ultrasound during routine antenatal care visits. Chest X-ray was free for 
all diagnosed cases. The sensitivity of ultrasound in diagnosis of molar pregnancy was calculated to 
be 87% while the sensitivity, specificity, positive predictive value, negative predictive value, and 
accuracy of ultrasound in differentiating complete and partial moles is presented in table 3 which 
were found to be 96.7%, 73.6%, 85.2%, 93.3%, and 87.7% respectively.  
Table (1): Demographic data of newly diagnosed cases of GTD in one year. 
Variables 
The study group     (n=62) 
No % 
Age (years) 
<18 
18 to <40 
≥40 
 
10 
44 
8 
 
16.1% 
71.0% 
12.9% 
Mean ± SD 
(Min.-Max.) 
26.22±9.30 
16-52 
BMI* 
Mean ± SD 
(Min.-Max.) 
 
24.55±4.01 
19-35 
Parity 
Nullipara & Primi para 
Multipara 
 
33 
29 
 
53.2% 
46.8% 
Mode of delivery  (n=42) 
Cesarean section 
Vaginal delivery 
 
24 
18 
 
57.1% 
42.9% 
History of miscarriage 22 35.5% 
Medical  diseases 
Anemia 
Asthma 
Diabetes 
Hypertension 
Hyperthyrodism 
Hypothyrodism 
Deep venous thrombosis 
n=23 
15 
2 
2 
1 
1 
1 
1 
37.1% 
65.2 
8.7 
8.7 
4.3 
4.3 
4.3 
4.3 
Positive family history 1 1.6% 
     *BMI: Body Mass In 
   Positive family history**: Recurrent CHM was diagnosed in her 2 sisters. 
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Table (2): Clinical presentation of the studied cases: 
Clinical presentation       (n=62) No % 
Diagnosed by ultrasound 33 53.2 
Vaginal bleeding 21 33.9 
Hyperemesis gravidarum 4 6.5 
Lower abdominal pain with pregnancy 2 3.2 
Stoppage of menstrual cycle above 50 years old 1 1.6 
Early onset Preeclampsia* 1 1.6 
(*) One patient was admitted in the Neurology department because of convulsive fits and was 
diagnosed to have early onset preeclampsia with molar pregnancy. 
Table (3): Accuracy of ultrasound in differentiating complete and partial moles. 
U/S 
Diagnosis 
 Histopathology 
Total 
Complete mole Partial mole 
Complete mole 29 5 34 
Partial mole 1 14 15 
Total 30 19 49 
Sensitivity: 96.7%                       Specificity: 73.6%                           PPV: 85.2% 
NPV: 93.3%                                   Accuracy: 87.7% 
In table 4, complete and partial mole were compared regarding the demographic and clinical data; 
the age and existence of bilateral theca lutein cysts were significantly different between two types 
of moles (P= 0.045 & 0.024 respectively), there were no significant differences regarding pre-
evacuation hCG (P = 0.29), and mean time to hCG normalization (P = 0.16).The rate of hCG 
decline after complete and partial molar evacuation was shown in figure 1.The percentage of cases 
which transformed to GTN is 24.2% in complete mole and 8% in partial mole (P = 0.105). 
Table (4): Comparison between complete and partial mole regarding demographic and 
clinical data  
Variables 
Complete mole (n=33) 
57% 
Partial mole        (n=25) 
43% 
p-value 
Age/years 27.66±10.71 23.20±5.53 0.045 
<18 
18-<40 
≥40 
7 (21.2%) 
21 (63.6%) 
5 (15.2%) 
3 (12.0%) 
21 (84.0%) 
1(4.0%) 
0.199 
BMI 25.00±4.07 23.88±3.51 0.276 
Parity 
Null& Primi para 
Multipara 
 
19 (57.6%) 
14 (42.4%) 
 
13 (52.0%) 
12 (48.0%) 
0.672 
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Gest. Age (weeks) 8.75±2.30 9.72±3.12 0.183 
Mode of delivery 
Caesarean Section 
Vaginal Delivery 
 
12 (54.5%) 
10 (45.5%) 
 
12 (66.7%) 
6 (33.3%) 
0.436 
History of abortion 11 (33.3%) 9 (36.0%) 0.832 
Med. Disease 7 (29.2%) 8 (33.3%)  
Complaint 
Vaginal Bleeding 
Hyperemesis 
diagnosed by U/S 
PET 
Pelvic Pain 
 
9 (27.3%) 
3 (9.1%) 
21 (63.6%) 
0 (0.0%) 
0 (0.0%) 
 
11 (44.0%) 
1 (4.0%) 
11 (44.0%) 
1 (4.0%) 
1 (4.0%) 
0.324 
Theca Leutin Cysts 
Free 27 (81.8%) 25 (100%) 
0.024 
Bilateral and  > 6 cm 6 (18.2%) 0 (0%) 
Blood transfusion need 
during evacuation 
 
23 (69.7%) 
 
12 (48.0%) 
0.094 
Mean pre-evacuation 
hCG (m.i.u/ml) 
Median (Min-Max) 
Mean ± SD 
 
88810 (3210-831000) 
162970± 190737 
 
65109 (4300-780000) 
107230± 161652 
0.29 
Mean time to hCG 
normalization (weeks) 
Median (Min-Max) 
8.5 (5-60) 
11.37±10.8 
10 (5-16) 
10.26±2.37 
0.16 
Progression to GTN 8/33 (24.2%  ) 2/25 (8% ) 0.105 
Figure (1): Comparison between complete and partial mole regarding different hCG levels 
before and after evacuation. 
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Fourteen GTN cases were reported; ten cases resulted progression of molar cases during follow up 
and four cases initially presented as GTN. All cases were low-risk (FIGO score 1-5). One case of 
invasive mole aged 42 years was treated with upfront hysterectomy with one course of 
methotrexate. Thirteen cases received 8 days regimen of intramuscular methotrexate-folinic acid; 
two of them failed to respond and were shifted to EMA/CO (etoposide, methotrexate, actinomycin 
D, cyclophosphamide and vincristine combination). One of these two cases who failed to 
combination chemotherapy underwent local myometrial resection followed by 2 courses of 
EMA/EP (etoposide, methotrexate, actinomycin D, etoposide, cisplatin) followed by hCG 
normalization.   
Discussion 
We reported for first time hospital -based and population – based incidence of molar pregnancy in 
Lower-Egypt population of 13.1 and 0.37 per 1000 live births respectively.  Since data on the total 
number of pregnancies are not available; the denominator is live births which underestimate the 
population at risk which may result in a small overestimation of the incidence rates observed in the 
current study. The hospital-based incidence is more than reported in Taiwan (8.0 per 1000 
deliveries), Indonesia (9.9 per 1000 pregnancies). Furthermore, our population based incidence is 
less than reported in the Netherlands (0.68 per 1000), Japan (3.0 per 1000) and England (1.54 per 
1000) [19]. However, In Egypt and many developing countries spontaneous abortions specimens 
are not routinely subjected to histopathologic review and registration. 
 In this study, the mean age was 26.22±9.30 years with 71.0% of the cases between 18 and 40 years 
old which is quiet understandable as this is the child bearing age period for women with the 
maximum number of pregnancies which reported also by other authors [20-22]. The mode of 
delivery of the studied cases was; 57.1% caesarean deliveries and 42.9% vaginal deliveries which is 
compatible with the increasing trend in caesarean section rates in Egypt [23]. The percentage of the 
cases with previous history of abortion was 35.5%, a history of prior spontaneous abortion has been 
reported to give women a two to three-fold increase in molar pregnancy compared to a woman 
without such a history [24]. Anemia was the most common medical disease affecting 65.2% of the 
studied cases which goes with the previous studies concerning anemia among pregnant women in 
Egypt [25].  
In this study we found that 53.2% of molar pregnancies were asymptomatic and accidentally 
discovered by ultrasonography which agreed with Joneborg et al [26] who reported that patients 
with vesicular mole were diagnosed before the onset of symptoms in 42.5% of cases, while Sun SY 
et al [27] reported that the most common presentation was vaginal bleeding in 46% compared with 
Ch. 2 │  Incidence and outcome of gestational trophoblastic disease in Lower Egypt 
 
26 
33.9% in the current study. The sensitivity of ultrasound for accurately diagnosing hydatidiform 
mole was 87%, though Fowler et al and Kirk et al [28] reported that the sensitivity of ultrasound for 
accurately predicting hydatidiform mole was 44%. This discrepancy may be attributed to small 
sample size of our study. 
The median level of hCG decline after molar evacuation for any type of GTD was 9 weeks which is 
earlier than reported by Delattre et al which was 12.3 weeks [29] which may explained by different 
patient criteria. Furthermore, we found that the GTN sequel during follow up was 10 cases (16.1%). 
Joneborg et al [30] reported that the risk of post-molar GTN was 8% in his study, though Schmitt et 
al [31] found that GTN developed in 12.1% of his cohort study. The variation of molar progression 
to GTN in different studies may reflect different outcome among different countries. 
In literature a wide range of ratios of complete mole to partial mole incidence has been reported 
ranging from 0.3 to 3.0 [32]. In the present study; 33 complete mole case to 25 partial mole cases of 
total 58 cases with a ratio of 1.3. Morphologically, both complete mole and partial mole have 
distinct histopathological features; however, the subjective nature of the morphological characters 
may give rise to variation in diagnosis [33]. In particular when earlier evacuation is performed in 
the present ultrasound era, classic morphological features may be less distinct [34]. The 
differentiation between molar and non-molar gestations is usually clear in cases showing typical 
histological features, and in cases of complete mole this is confirmed by p57 immunohistochemistry 
[35]. However, the diagnosis of partial mole can still be confusing, even to specialized 
gynecological pathologists [36] and this is important clinically in view of the risk of GTN 
progression in these patients. Moreover, hydropic abortion has traditionally been considered the 
major differential diagnosis of partial mole [37]. 
The trend toward earlier diagnosis for both complete mole and partial mole observed in our center is 
consistent with the global trends as the median gestational age at evacuation was 8.75±2.30 weeks 
for complete mole and 9.72±3.12 weeks for partial mole. Sun et al reported The 
median gestational age at evacuation was 9 weeks for complete mole and 12 weeks for partial mole 
[38] and reported in another study [29] that the median gestational age at diagnosis continued to 
decrease in two non-concurrent cohorts (1988-1993 versus 1994-2013) of patients from the New 
England Trophoblastic Disease Center; 9 weeks versus 12 weeks. Blood transfusion was required 
during evacuation of 69.7% of cases of complete moles and 48.0% of partial moles. This figure is 
much more than reported by authors at the New England Trophoblastic Disease Center [39]. The 
high rate of blood transfusion in our study may be attributed to higher incidence of anemia in 
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Egyptian pregnant women which was reported by some authors [25] and correlated to high 
prevalence of anemia among the studied cases that was 65.2%.  
The current study has limitations that Mansoura University Hospital is a regional referral center, 
and, therefore, our patient population may not be representative of the entire patient population. The 
reported data could be influenced by referral bias. Furthermore, immunohistochemical staining with 
P57 is not used routinely to differentiate between partial and early complete moles which may result 
in relatively higher incidence of partial moles. Centralization of GTD work allows proper 
estimation of incidence, sharing expertise at the national level, and help implementation of clear 
guidelines of diagnosis and treatment of GTD cases [40].  
Conclusion 
The incidence of molar pregnancy and GTN at Mansoura University Hospitals is estimated to be 
13.1 and 3.2 per 1000 live births respectively. Ratio of complete to partial moles was 1.3. Fifty-
three percent of the cases were accidentally discovered by ultrasound. We found no significance 
between CM and PM regarding mean pre-evacuation hCG level, mean time to hCG normalization, 
and rate of progression to GTN which need to be verified in future studies. 
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 Abstract  
Background 
The value of second uterine curettage in postmolar gestational trophoblastic neoplasia (GTN) is presently 
unclear. In a randomized study of low-risk postmolar GTN, we investigated the effect of second uterine 
curettage on the number of chemotherapy courses and relapse rate, and on variables associated with the 
number of chemotherapy courses. 
Methods 
Eligibility criteria were age 18 or over, WHO low or intermediate risk score for postmolar GTN, serum β 
human chorionic gonadotropin (hCG) level ≤ 5,000 IU / L, and fit for treatment with methotrexate. 
Exclusion criteria were previous uterine perforation and/or life-threatening bleeding. Randomization was 
performed (1:1) to a second curettage (intervention) or no curettage (control) group before methotrexate 
treatment, stratified for hCG level and vaginal bleeding. The primary outcome was the number of 
chemotherapy courses required for hCG normalization. Secondary outcomes were need for second-line 
treatment, toxicity, relapse rates, and variables associated with number of chemotherapy courses. The study 
was registered in the Dutch Trial Registry (NTR3390).  
Results 
Eighty-six consecutive patients presenting with postmolar GTN were included in the intention to treat 
analyses. Groups were comparable with regard to demographics and patient characteristics. Surgical 
complications did not occur. The mean number of chemotherapy courses required to reach hCG 
normalisation was 4.4 ± 2.2 (standard deviation (SD)) in the control group versus 3.8 ± 2.3 SD in the 
intervention group (p = 0.14). Groups were comparable in terms of second-line treatment needed to reach 
hCG normalisation (3 and 4 cases, respectively), and relapse within the first year (2 and 1 cases, 
respectively).  
Conclusion 
Second uterine curettage has no impact on the number of chemotherapy courses required or on the 
rate of relapse in low-risk postmolar GTN patients. 
 
 Key words:  
Gestational trophoblastic neoplasia; treatment; Second uterine curettage. 
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Introduction. 
Gestational trophoblastic neoplasia (GTN) includes postmolar GTN [1], which is typically 
diagnosed in asymptomatic women undergoing routine serum hCG monitoring after evacuation of a 
complete or partial molar pregnancy [2]. Following diagnosis of postmolar GTN, staging and risk 
assessment (mostly using FIGO staging and the modified World Health Organisation (WHO) 
Prognostic Scoring System as adapted by FIGO)[3] distinguishes patients at low versus high-risk, 
which influences subsequent decisions on the specific chemotherapy regimen. At present, most low-
risk (WHO risk score 0–6) GTN patients are treated with single-agent methotrexate or actinomycin 
D [4], and remission rates of 90% and over are obtained in stage I disease, compared to rates of 
approximately 70% in stage II and stage III disease[4,5]. 
The role of second uterine curettage, as a single or additional treatment, in the management of 
postmolar GTN is unclear. Previous retrospective studies found widely differing cure rates, varying 
between 9 and 80% [6,7]. A debulking effect of second uterine curettage has been shown in two 
retrospective analyses which reported that fewer chemotherapy courses were needed to reach 
undetectable serum hCG levels after second curettage[6,8]. This reduction seems to be related to 
serum hCG level and the presence or absence of myometrial invasion and distant metastases.  
Recently, two prospective observational studies were published, including a small prospective pilot 
study which reported cure in ten out of twelve patients after second curettage in postmolar GTN [9]. 
The second, a study performed by the Gynecologic Oncology Group, reported cure rates of 40% for 
low-risk non-metastatic GTN using second uterine curettage as a single treatment [10]. The 
disadvantages of second uterine curettage include complications such as uterine perforation, 
infection and bleeding, and a delay in starting chemotherapy when post-curettage hCG levels fail to 
normalise [10]. 
In a single-centre, randomized phase II trial in low-risk postmolar GTN patients, we investigated 
the effect of second uterine curettage on the number of chemotherapy courses needed to achieve 
hCG normalisation, and on the toxicity and relapse rates. We also aimed to identify variables 
associated with the number of courses required for successful treatment.  
Methods 
Study design and participants 
In this randomised, controlled phase II trial, carried out in a single university centre in Mansoura, 
Egypt, consecutive patients with low-risk postmolar GTN and serum hCG levels ≤ 5,000 IU/L were 
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considered eligible. The Mansoura University Hospital provides tertiary healthcare for most of the 
Delta region of Egypt, with a population of about 12 million. Most of the required treatments 
(second uterine curettage, methotrexate and folinic acid) were provided free of charge to reduce the 
cost burden on patients and to minimize drop-out. 
Eligible participants were women aged 18 or over with a postmolar GTN, with a WHO low or 
intermediate risk score, a serum hCG level ≤ 5,000 IU/L, and fit for standard treatment with 
methotrexate. Exclusion criteria were previous uterine perforation and/or life-threatening bleeding. 
Patients gave written informed consent before inclusion in the study. The study was approved by 
the ethical committee of the Faculty of Medicine, Mansoura University (Number R/48) and was 
registered in the Dutch Trial Registry (NTR3390). 
Randomization 
Patients were randomized (1:1) by means of a web-based system, using random block sizes, at the 
Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands. The patients 
were stratified according to the presence or absence of vaginal bleeding and the level of baseline 
serum hCG, i.e., < 1,500 IU/L or 1,500-5,000 IU/L.  
Procedures 
At baseline, all patients underwent a pelvic transvaginal ultrasound examination to measure the 
dimensions of intra-uterine disease (mm2), calculated as the product of the longest versus the 
perpendicular diameter of the uterine lesion. In addition, patients underwent a staging chest X-ray 
and hCG measurement (assay used not specified, normal value < 7 IU/L). Central pathology review 
of the primary curettage was not performed.  
Second uterine curettage was performed under short-acting general anaesthesia or sedation, and 
antibiotic prophylaxis. After cervical dilatation the uterine cavity was evacuated using manual 
vacuum aspiration under ultrasound guidance (Ipas MVA EasyGrip® Cannulae, Ipas, Chapel Hill, 
NC 27515 USA) [11,12]. Tissue obtained was sent for histopathological analyses. 
All patients received standard methotrexate treatment with folinic acid support, both given 
intramuscularly in a 2-weekly regimen. Methotrexate was administered at a dose of 50 or 75 mg 
(the latter for women exceeding 75 kg) on days 1, 3, 5 and 7, alternating with folinic acid at a dose 
of 12.5 mg on days 2, 4, 6 and 8. The first methotrexate course was given during admission, and 
subsequent courses were given at the woman's home by a trained nurse. After normalisation of 
serum hCG, two consolidation courses of methotrexate were given.  
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Before each course of chemotherapy, a complete blood cell count, kidney and liver function tests, 
and serum hCG were evaluated. Adverse events were defined and graded using Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0 [13]. In patients who experienced severe 
toxicity or failure of methotrexate, treatment was abandoned and further management was given 
according to tumour board recommendations. Methotrexate failure was deemed to be a plateau or 
decline of less than 10% in hCG levels over 3 courses, or a rise in the hCG level of more than 10% 
above the prior obtained value over two consecutive courses. In case of methotrexate failure or 
relapsed GTN, re-staging was performed. The choice of second-line chemotherapy was 
individualized according to disease status, tumour board recommendations and drug availability. 
During and after treatment, patients were strictly advised not to become pregnant. Follow-up was 
performed by monthly testing of serum hCG levels for a year after normalization of hCG. 
Primary and secondary outcome measures 
The primary endpoint was the mean number of chemotherapy courses needed to achieve hCG 
normalisation. Secondary endpoints were "successful treatment", defined as normalization of serum 
hCG level by methotrexate only and without relapse within one year. "Second-line treatment" was 
defined as treatment after methotrexate failure, the need for emergency surgery and any treatment 
for relapse during follow-up. Other secondary endpoints were length of chemotherapy cycles, 
complications and toxicity of methotrexate, the need for surgery, and variables associated with the 
number of methotrexate courses until hCG normalisation.  
Statistical analyses  
Based on previously published data, we expected to find a mean reduction from 4.8 chemotherapy 
courses to 2.5 courses before hCG normalization [6,8]. With a two-sided 5% significance level, a 
power of 99%, and an expected dropout rate of 10%, a sample size of 44 patients per group was 
necessary to detect this difference. We anticipated that a 36-month inclusion period would be 
required to recruit this number of patients. 
Analyses were performed as intention-to-treat. Sociodemographic characteristics and treatment 
outcomes between the two arms were compared using the Mann-Whitney U test for continuous 
variables and the Kruskal-Wallis test for categorical variables. Linear regression was performed to 
study the effect of second uterine curettage and other variables on the number of chemotherapy 
courses needed. A negative odds ratio (OR) means the variable was associated with fewer 
chemotherapy courses. To study the effect of several variables on treatment success, which is a 
dichotomous outcome, logistic regression was performed. An OR below one means the variable 
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was associated with less frequent treatment success. Multivariable regression analysis was 
performed with all relevant variables, with a maximum degree of freedom of 1 per 10 patients. 
Statistical tests were two-sided and p-values were considered statistically significant when p < 0.05. 
Statistical analyses were carried out using the statistical package SPSS 22 for Windows (SPSS, 
Chicago, IL, USA).  
Results 
Between October 2011 and February 2016, 123 patients with postmolar GTN were seen at the 
Mansoura Trophoblastic Clinic, of whom 34 were excluded for the following reasons; 26 patients 
did not fulfil the eligibility criteria, five eligible patients refused randomization, two started 
treatment in another hospital, and one needed immediate emergency surgery for severe uterine 
bleeding. Consequently, 89 consecutive patients were enrolled in the study. After randomization 
three patients were excluded; one chose hysterectomy in another hospital, the second refused 
subsequent treatment when methotrexate failed and was lost to follow-up, and the third ultimately 
did not fulfil the diagnostic criteria of postmolar GTN. Therefore, 86 patients were finally included 
in the intention-to-treat analyses (figure 1).  
Patient groups were comparable for age, parity, hCG level, type of preceding mole, size of uterine 
mass, WHO performance score, weight and BMI (table 1).  
 
Table 1. Sociodemographic data 
 Methotrexate 
N = 43 
Second curettage and 
methotrexate N = 43 
P value 
Age in years Mean(SD) 26.6 (6.4) 25.8 (7.7) 0.63 
Parity    
0.62 • Nulliparous  12 10 
• Parous 31 33 
Preceding pregnancy    
0.65 • Complete mole 29 27 
• Partial mole 14 16 
hCG pattern   
0.63 
• Rising 27 30 
• Plateau 13 12 
• Persistent 3 1 
Vaginal bleeding   
0.28 • Vaginal bleeding present 28 23 
• No vaginal bleeding 15 20 
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WHO score   
0.49 
• 0 1 0 
• 1 33 32 
• 2 9 11 
Uterine mass (mm2) Mean(SD) 139 (19) 171 (27) 0.46 
βhCG level (IU/L) 3000 (1974) 3274 (1813) 0.59 
Weight 75.5 (12.4) 71.5 (10.5) 0.09 
BMI 26.9 (3.3) 26.5 (3.0) 0.46 
[ 
 
Table 2. Treatment outcome 
 Methotrexate 
(n = 43) 
Second curettage and 
methotrexate  (n = 43) 
P 
value 
Mean number of courses to reach normalization 
of βhCG (SD)(*)  
4.4 (2.2) 3.8 (2.3) 0.14 
Mean duration of single cycle (days) (SD) 17.9 (4.1) 17.9 (4.6) 0.58 
Complications of methotrexate (^) 
  
0.57 
• None 30(69.8%) 28(65.1%) 
• at least one complication 13 (30.2%) 15(34.9%)  
▪ Grade 1   
          Pharyngitis 9 (20.95) 6 (14.0%) 
          Colic pains 3 (7.0%) 3 (7.0%) 
▪ Grade 2   
          Fatigue 15 (34.9%) 13 (30.2%) 
          Oral Ulcers 8 (18.6%) 7 (16.3%) 
          Vaginal bleeding, requiring intervention 1 (2.3%)  
▪ Grade 3   
          Vaginal bleeding requiring surgery (°) 2 (4.7%)  
Treatment outcome    
0.77 
• Successful 36 (83.7%) 37 (86.0%) 
• Combination chemotherapy after 
methotrexate failure 
• Need for emergency intervention 
3 (6.9%) 
2 (4.6%) 
4 (9.3%)  
• Relapse < 1 year 2 (4.6%) 1 (2.3%) 
• Choriocarcinoma after subsequent pregnancy  1$ (2.3%) 
Histology#    
• Molar tissue 2 (4.6%) 35 (83.3%) 
• Nonmolar tissue  7 (16.7%) 
• Choriocarcinoma  1$ (2.3%) 
Follow -up   
0.96 
• Duration (months) 23 (14) 23 (13) 
• Lost to follow-up 2 1 
• Pregnancy within 12 months after 
normalization of βhCG 
7 6 
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(*) Sum of methotrexate and second-line treatment in the first episode. 
(^) Grades of complications according to CTCAE criteria13. A patient can suffer from more than one 
complication.  
(°) Emergency curettage (n = 1) and emergency hysterectomy (n = 1). 
($) Diagnosis of invasive choriocarcinoma shortly after delivery of the subsequent pregnancy.  
(#) In the standard methotrexate group, histology was obtained twice; once by emergency curettage for 
bleeding, and once by emergency hysterectomy after methotrexate failure. In the intervention group, 
histology was missing for one curettage. The choriocarcinoma was diagnosed after a subsequent pregnancy 
in a case where the second curettage showed no molar tissue. 
 
The mean number of chemotherapy courses required for hCG normalization was comparable for the 
control group, 4.4 ± 2.2 SD, and the intervention group, 3.8 ± 2.3 SD (p = 0.14) (table 2). Mean 
cycle duration was 17.9 days in both groups. Results of the unforeseen substandard care analyses 
and details on unsuccessful cases are described in supplementary table 1. Methotrexate failure was 
similar for both groups; in three control cases and four intervention cases, respectively. During the 
first year of follow-up, disease relapse occurred in two patients in the control arm and in one patient 
in the intervention group, also in the intervention group one patient was diagnosed with 
choriocarcinoma after a subsequent full term pregnancy. 
According to protocol, all cases received two consolidation courses after normalization of hCG, 
except for three cases who received only one consolidation course, due to use of an earlier protocol. 
None of the latter experienced a relapse.  
No surgical complications occurred in the intervention group. Side effects of methotrexate occurred 
in 28 patients (32.6%), comprising 15 patients in the control group and 13 in the intervention group 
(table 2), with predominantly grade 1 and 2 adverse effects. Two patients in the control group 
developed grade 3 adverse effects, i.e. severe vaginal bleeding necessitating surgical intervention; 
one patient underwent emergency uterine curettage and the other underwent hysterectomy on day 6 
of the second methotrexate course. In the intervention group one patient requested a hysterectomy 
when methotrexate failure occurred after the third methotrexate course (see supplementary table 1).  
Tables 3 and 4 depict the number of courses needed to reach hCG normalisation in relation to 
patient characteristics. Linear regression analyses showed that only serum hCG level was 
statistically significantly related to the number of chemotherapy courses needed. In addition, after 
adjustment for factors including baseline hCG level, vaginal bleeding, weight and cycle duration in 
multivariable regression analyses, second uterine curettage did not significantly reduce the number 
of courses needed to reach normalization of hCG (OR -1.04 95% CI -2.54; 0.46, p = 0.17). There 
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was also no relation between baseline serum hCG level and uterine dimensions (Pearson correlation 
coefficient 0.164 (p = 0.132)).  
Histopathology after second uterine curettage was available for 42 of 43 cases, revealing molar 
tissue in 35 patients (83%) and only endometrial tissue in seven patients (17%). The 
histopathological finding of molar tissue was not predicted by the dimensions of the uterine mass; 
the mean dimensions for women with molar tissue was 208 ± 293 mm2, compared to 96 ± 222 mm2 
for women with only endometrial tissue (p = 0.34).  
 
Table 3. Number of courses in relation to patient characteristics  
 Methotrexate 
(n = 43) 
Second curettage and 
methotrexate (n = 43) 
Bleeding    
• Vaginal bleeding (28 / 23) 4.0 (2.2) 3.5 (1.6) 
• No bleeding (15 / 20) 5.1 (2.2) 4.2 (2.9) 
hCG pattern   
• Rising (27 / 30) 4.4 (1.9) 3.7 (2.1) 
• Plateau (13 / 12) 4.4 (3.0) 3.9 (2.7) 
• Persistent (3 / 1) 3.3 (1.5) 4 (--) 
hCG level   
• continuous (3000 / 3274) 5.31 ∙ 10-4 4.25 ∙ 10-4 
• < 1500 (15 / 12) 2.8 (1.9) 2.8 (0.8) 
• 1500-5000 (28 / 31) 5.2 (1.9) 4.2 (2.5) 
Weight   
• continuous (75,6 / 71.5) 0.001 (-0.056, 0.058) 0.03 (-0.04, 0.94) 
• ≤ 65 (9 / 15) 4.0 (2.3) 3.4 (1.6) 
• > 65 (34 / 28) 4.4 (2.2) 4.0 (2.5) 
Mean length of single course   
• continuous (17.9 / 17.9) -0.03 (-0.20, 0.14) -0.05 (-0.20, 0.11) 
• ≤ 16 days (16 / 19) 3.5 (2.0) 4.0 (2.4) 
• > 16 days (27 / 24) 4.9 (2.3) 3.7 (2.2) 
Treatment outcome    
• Successful (36 / 37) (*) 
• second-line treatment (7 / 6) 
4.0 (2.0) 
6.3 (2.6) 
3.3 (1.4) 
6.8 (4.1) 
Histology    
1 = Molar tissue (NA / 34) 
2 = No molar tissue (NA / 7) 
Not applicable 3.6 (2.1) 
3.6 (0.5) 
(*) "Successful treatment" is defined as reaching normalization of serum hCG level using methotrexate 
alone, with uneventful follow-up. 
"Second-line treatment" is defined as methotrexate failure and subsequent second-line chemotherapy, the 
need for emergency surgery and treatment for relapse.  
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Table 4. Linear regression: effect of several factors on number of courses 
(*) A negative OR means that fewer courses were needed to reach normalisation of hCG.  
 (^): low hCG < 1,500 IU / L, high hCG between 1,500 and 5,000 IU/L  
Table 5. Linear regression: effect of several factors on treatment success (*) 
(*)"Successful treatment" is defined as reaching normalization of serum hCG level using methotrexate alone, 
with uneventful follow-up. (i.e., 36 out of 43 in the control group, and 37 out of 43 in the intervention 
group).  
Patients were advised to undergo monthly hCG monitoring for a year and to refrain from pregnancy 
during this period. Three cases were lost to follow-up, and 13 (15.1%) got pregnant within 12 
months (table 2). One of them accepted an induced abortion, two suffered first trimester pregnancy 
loss, one developed a second molar pregnancy, and in one pregnancy the foetus had congenital 
intestinal obstruction. The eight other pregnancies resulted in a healthy baby.  
 OR 95% CI P value 
Curettage  -0.54 (*) -1.50; 0.43 0.27 
hCG level    
• As continuous variable 4.69 (∙10-4) 2.32(∙10-4); 7.07(∙10-4) <0.001 
• High versus low (^) 1.85 0.88; 2.81 <0.001 
Plateau and persistent hCG versus 
rising hCG 
-0.02 -1.05; 1.01 0.97 
No bleeding versus vaginal bleeding 0.78 -0.20; 1.75 0.12 
weight    
• As continuous variable 0.02 -0.03; 0.06 0.47 
• >65 kg versus ≤ 65kg 0.63 -0.44; 1.71 0.24 
Cycle duration    
• As continuous variable -0.04 -0.15; 0.07 0.47 
• >16 days versus ≤ 16 days 0.57 -0.41; 1.55 0.25 
 OR 95% CI P value 
Curettage  1.20 0.37; 3.91 0.76 
hCG level    
• As continuous variable 1.0003(∙10-4) 1.00(∙10-4); 1.001(∙10-4) 0.07 
• High versus low 6.64 0.82; 54.0 0.08 
Plateau and persistent hCG versus 
rising hCG 
1.28 0.38; 4.32 0.70 
No bleeding versus bleeding 1.30 0.40; 4.26 0.66 
weight    
• As continuous variable 1.03 0.97; 1.08 0.34 
• >65 kg versus ≤ 65kg 1.35 0.4; 5.38 0.67 
Cycle duration    
• As continuous variable 1.03 0.91; 1.17 0.63 
• >16 days versus ≤ 16 days 2.60 0.66; 10.24 0.17 
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Treatment success rate was similar for both groups (table 5). After adjustment for hCG level, 
vaginal bleeding, weight and mean cycle duration, success rates of methotrexate treatment were 
similar in both treatment groups (OR 0.86 (95% CI 0.24; 3.06, p = 0.81) (table 5). 
Discussion 
From this randomized study we conclude that second uterine curettage does not significantly impact 
the number of chemotherapy courses in patients with postmolar GTN. Our results are in line with 
one retrospective study that concluded that dilatation and curettage of GTN does not affect future 
chemotherapy requirements [14], and contrast with two other retrospective analyses [6,8]. In a 
recently published, prospective Gynaecologic Oncology Group study, 26 of 64 (40%) patients did 
not need chemotherapy after a second curettage [10]. In our study all women were treated with 
methotrexate, and a possible definitive curative effect of second curettage was not awaited. It is 
therefore conceivable that the inclusion of women cured by second curettage (i.e., not receiving any 
chemotherapy) in some retrospective studies led to a lower overall number of chemotherapy 
courses. However, it should be noted that it is still unclear whether awaiting the curative effect of 
second curettage affects the total duration of treatment in cases where second curettage fails. 
The above mentioned studies suggest that two factors influence the likelihood of reducing the 
number of chemotherapy courses required to reach hCG normalization, namely the presence of 
vaginal bleeding and the pre-curettage hCG level. Severe vaginal bleeding can lead to prompt 
surgical treatment, illustrated in our study by two women in the control arm undergoing emergency 
surgery for severe bleeding. Since we performed an intention to treat analysis and stratified for 
vaginal bleeding at presentation, this did not affect the study results. In UK guidelines, the presence 
of a uterine mass in combination with hCG levels below 5,000 U/L will prompt second curettage 
[15]. Although all women in the current study had a uterine mass, ultrasound findings did not 
correlate to the hCG level, nor to the presence of molar tissue at curettage. It is therefore debatable 
how well the presence of molar tissue is predicted by ultrasonography. While the numbers included 
in the present study prohibit conclusions on the success or failure of second curettage in the absence 
of molar tissue in the pathology specimen, it would be reasonable to conclude that second curettage 
is not beneficial without histological evidence for molar tissue. Although all cases in our study had 
relatively low hCG levels pre-curettage, initial hCG levels were still related to the number of 
courses required for normalization. However, when we compared women with hCG levels < 1,500 
to women with hCG levels between 1,500 and 5,000, the second curettage did not have an impact 
on the number of courses needed for normalization of serum hCG levels. 
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Failure of methotrexate occurred in seven patients and relapse after therapy in four, including a case 
with a choriocarcinoma after a subsequent full term pregnancy (table 2 and supplementary table 1). 
Including the two women who underwent emergency surgery, 15% of the patients needed some 
form of second-line treatment. This is in line with previous reports [16,17]. 
Limitations of the study:  
This study was performed in a single centre, whereas a multicentre setting would be preferable. 
However, this study and the Gynecologic Oncology Group study are the first prospective studies 
done, and both showed slow accrual due to the low incidence in most countries. In our study hCG 
monitoring was carried out at several laboratories, while a standardized test would be preferred. 
Given local circumstances and resources, the current study therefore reflects daily practice. 
Although three patients (3%) were lost to follow-up, this seems acceptable given the projected loss 
of 10%. Fifteen percent of women got pregnant within 12 months, pregnancy outcomes are 
available for all participants, and therefore it is unlikely that this influenced the outcome of the 
study. 
Methotrexate chemotherapy is generally given in a 2-weekly cycle. In the current study the mean 
treatment cycle duration was 17.9 days in both groups, and thus unlikely to have impacted the 
primary study outcome. This observation prompted a substandard care analysis, in which we 
observed several factors of notice. These included patient-related factors, such as a reluctance to 
perform blood tests on-time, reluctance to switch to a second-line treatment, difficulties in reaching 
the clinic, and financial burdens, whereas others were external factors such as poor availability of 
methotrexate or other second-line drugs in Egypt due to political factors.  
Methotrexate is available in vials of 50 mg, and the methotrexate dose in our study was 
administered in a fixed dose (50 or 75mg), allowing subsequent courses to be administered by a 
nurse in a home setting. The (international) discussion on the best methotrexate dosing regimen is 
not yet settled, and some favour a dose related to body weight (1mg/kg) rather than a fixed dose. 
Since the two treatment groups were comparable regarding body weight and BMI, the regimen and 
dosing in this study is unlikely to have affected the primary outcome. 
Accurate classification of molar specimens into complete or partial moles is important for accurate 
assessment of the risk of postmolar GTN, with complete moles carrying a significantly higher risk 
of postmolar GTN (15–20%) than partial moles (0.2–4%) [18-21]. Some reports suggest that partial 
moles are more common and have higher risk of subsequent GTN in non-western countries [22,23]. 
Therefore, one of the original secondary endpoints described in the study protocol was the relation 
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between histopathology and the number of courses needed for normalisation of hCG. However, we 
decided to refrain from analysing this point, since it was not possible to obtain all original curettage 
tissues for central pathology review, and secondly, because molecular genotyping was not available 
[24].  
Conclusion 
Second uterine curettage has no impact on the number of chemotherapy courses required or on the 
rate of relapse in low-risk postmolar GTN patients. 
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Supplementary table 1: Summary of the failed cases. 
Study 
nr 
Age, 
parity  
hCG pattern 
and level prior 
to diagnose 
GTN 
Case description  Mean 
cycle 
duration 
(days) 
Substand
ard care 
factors 
Standard arm: Methotrexate (MTX) treatment (n = 7) 
6 18 y, 
P1 
Rising 4.000 Normalization of hCG after 4 
MTX courses, 2 
consolidation courses.  
Relapse 118 days after last 
MTX consolidation course.  
Second-line: 3 MAC + 2 
consolidation courses. 
19.3 3 times treatment delay  
30 29 y, 
P2 
Rising 5.000 Normalization after 7 MTX 
courses, 2 consolidation 
courses. 
Relapse 33 days after last 
MTX consolidation course. 
Second-line: 2 MAC + 2 
consolidation courses.  
14.3 None 
31 21 y, 
P3 
Rising 4960 Severe vaginal bleeding 6 
days after 2nd MTX course, 
not responding to medical 
treatment (blood transfusion, 
haemostatic's) 
Emergency hysterectomy: 
histology revealed invasive 
16.5 Only one consolidation 
course 
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mole. 
After hysterectomy she 
received 2 MTX + 1 
consolidation course 
42 30 y, 
P2 
Rising 5000 Failed MTX, plateau after 5 
courses. 
Second-line: 3 EMA/CO + 2 
consolidation courses. 
18.0 No hCG prior to 2nd and 3rd 
EMA/CO course. 
45 20 y, 
P0 
Plateau 5000 Failed MTX, plateau after 6 
courses. 
Second-line: 3 EMA/CO + 2 
consolidation courses. 
18.6 Delays in hCG check and 
MTX start 
No hCG prior to 2nd and 3rd 
EMA/CO course. 
69 31 y, 
P1 
Rising 2041 Severe vaginal bleeding after 
1st MTX course, not 
responding to medical 
treatment (blood transfusion, 
haemostatic's) 
Emergency curettage: 
histology revealed invasive 
mole 
Significant hCG drop after 
emergency curettage. 
After curettage she received 
2 MTX + 2 consolidation 
courses  
31.7 Delay due to severe bleeding 
and bad clinical condition.  
77 20 y, 
P0 
Plateau 2059 Failed MTX, rising hCG 
after 5th course 
Second-line: 4 EMA/CO + 2 
consolidation courses. 
17.2 Delays in hCG checks and 
MTX start 
No hCG prior to 2nd and 3rd 
EMA/CO course. 
Study arm: second curettage and MTX treatment (n = 6) 
9 27 y 
P3 
Plateau 
4.999 
Re-curettage: endometrial 
tissue 
Normalization after 4 MTX 
courses, 2 consolidation 
courses. 
Received contraceptive pills 
for 1 year then got pregnant. 
Delivered normal baby by 
caesarean section 
Severe haemorrhage 3 weeks 
postpartum 
Curettage: histology revealed 
choriocarcinoma 
Second-line: 3 MAC + 2 
consolidation courses. 
Uneventful follow-up for 12 
months  
16.8 None  
15 42 y, 
P5 
Plateau 4.950 Re-curettage: no histology 
done 
Failed MTX, plateau after 
8th course 
Second-line: 4 MAC + 2 
consolidation courses. 
18.1 Plateau should have been 
recognized after 3rd MTX 
course. 
20 23 y, 
P1 
Rising 5.000 Re-curettage: molar tissue 
Normalization of hCG after 3 
MTX courses, 2 
16.0 Treatment protocol 
violation, according to the 
protocol EMA/CO or MAC 
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consolidation courses.  
Relapse 78 days after last 
MTX consolidation course.  
Second-line: 2 MTX + 2 
consolidation courses. 
should have been given for 
second-line treatment. 
53 34 y, 
P3 
Rising 5000 Re-curettage: molar tissue 
Failed MTX, rising hCG 
after 3rd course 
Second-line: 3 EMA/CO + 2 
consolidation courses. 
18.2 No hCG prior to 2nd and 3rd 
EMA/CO course 
60 43 y, 
P4 
Rising 3250 Re-curettage: molar tissue 
Failed MTX, plateau of hCG 
after 3 courses, combination 
chemotherapy was refused, 
rising hCG after 7th course. 
Finally combination 
chemotherapy was accepted.  
Second-line: 5 EMA/CO + 2 
consolidation courses. 
15.5 Delay in switch to second-
line chemotherapy due to 
discussions with the patient 
and family. 
64 38 y, 
P5 
Plateau 1328 Re-curettage: molar tissue 
Failed MTX, rising hCG 
after 3rd course 
Tumour board advised 
EMA/CO or hysterectomy. 
After counselling 
hysterectomy was done: 
histology revealed invasive 
mole 
Second-line: 1 EMA/CO + 2 
consolidation courses. 
19.3 none 
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Most women facing gynaecological cancer live in countries with inadequate health systems and 
treatment is rarely in line with international standards. This is particularly true for cervical cancer, 
as most developing countries offer few opportunities for radiotherapy, leaving many women 
without proper treatment and the risk of avoidable mortality [1]. The Lancet recently highlighted 
the need to close the global cancer divide for women, but real progress will require not only 
evidence-based policy making, but also broad multisectoral collaboration and innovative public 
health approaches to cancer care and control [2]. The gynaecologic malignancy with the highest 
cure rate is gestational trophoblastic neoplasia (GTN). Postmolar GTN was studied at the Mansoura 
University Hospital, Egypt, with support from the Erasmus MC Cancer Institute, University 
Medical Center, Rotterdam, the Netherlands. The outcome of this study has implications for all 
women with GTN and we would therefore like to share our experiences, and at the same time 
advocate an increase in worldwide partnerships of researchers to improve our understanding of 
routine clinical problems.  
 
Outcome of the study in international perspective. 
In a randomized controlled trial, we studied the effect of second curettage in postmolar GTN on the 
number of methotrexate chemotherapy courses, and found that a second curettage did not reduce the 
number of courses needed to normalize serum human chorionic gonadotropin (hCG) levels [3]. 
Simultaneously, a multicentre prospective phase II study on the curative effect of re-curettage in a 
similar patient group, performed in Northern America by the Gynecologic Oncology Group (GOG), 
showed that a second curettage cured 40% of women with postmolar GTN [4]. Although the studies 
had different end points, we can conclude that second curettage is of value only when cure 
(normalisation of hCG) is awaited for. Together, the results of these studies finally settle the 
question of the role of second uterine curettage in postmolar GTN.  
 
Available collaborations. 
After the formation of the Gynecologic Cancer InterGroup (GCIG) the number of high-quality 
phase 3 trials at a global level have increased. However, most of the involved centres originate in 
developed countries. Also an analyses on the global patterns of collaboration on meta-analysis 
showed that most authors are from the larger centres from Northern and Western America and 
Europe [5]. Developing nations face many health challenges and lack the science, equipment, and 
financial infrastructure needed for research. Cooperation between the developing and the developed 
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world is therefore mandatory [6]. The benefits of collaborative projects extend well beyond 
scientific value alone. In this essay we would like to emphasize several of these "soft" aspects. 
 
Some studies are challenging in the developed world.  
Certain studies cannot be efficiently carried out in developed countries due to low disease incidence 
and decentralized treatment; a case in point is GTN. The difficulty in patient accrual is reflected in 
the two abovementioned studies; in the GOG study nine centres recruited 64 patients over a period 
of 5 1/2 years, whereas the single centre Egyptian study recruited 89 patients in 4 years, indicating 
that international collaboration can sometimes overcome problems of slow patient recruitment [6]. 
 
Collaboration improves the standard of care in the low income countries. 
Healthcare benefits that may arise from contributing to clinical research include improvements in 
local infrastructure, the processes of care and the workforce [7]. Due to our involvement in this 
study, practice at Mansoura Hospital has been evaluated and protocols updated in line with 
international standards. Other spin offs of this collaboration include the launch of the first 
trophoblast clinic in Egypt, which now serves as a referral centre for patients in the (wider) area, 
and the development in Arabic of a patient information leaflet on molar pregnancy. The trophoblast 
clinic has also established collaborations with sponsors to ensure that care remains available and is 
provided free of charge. Furthermore, this centre recognized that recurrent mole (i.e., three or more 
episodes of molar pregnancy) occurs more frequently than expected in the Egyptian Nile Delta 
(incidence figures not yet available). Moreover, collaboration with international experts was sought 
and chromosomal analyses performed, free of charge, in selected cases. This analysis resulted in the 
detection of mutations in several patients with recurrent molar pregnancies, and led to the discovery 
of a recently published novel mutation [8,9]. 
 
Collaboration improves the standard of research in the low income countries. 
Through these alliances colleagues who are unfamiliar with research practice are encouraged to 
adhere to international standards, beginning with a well-thought-out research protocol and proper 
recording of data, preferably using an electronic case record form. By engaging the resources of the 
supporting parties, such as internet-based randomization programs and access to international 
literature, the research capacity of colleagues in a low resource setting can be significantly 
enhanced. Collaborative analysis of data also allows for a better recognition of possible biases and 
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weaknesses of a study. The knowledge obtained through hands-on support can be transferred to 
other researchers and staff members, further enhancing the positive effects of a collaborative study. 
In the case of this particular study, the sharing of results via a consensus workshop on gestational 
trophoblastic tumours has allowed us to reach gynaecologists, pathologists and oncologists all over 
Egypt. Finally, the presentation of results at international meetings and publication in high impact 
journals benefits all researchers concerned. 
 
Collaboration improves mutual understanding. 
Persistent GTN is one of the few neoplasias with a very high cure rate, when treated appropriately. 
However, colleagues in low resource countries often encounter problems unimaginable for 
professionals in the developed world. A range of challenges can frustrate effective treatment: 
Economic and political issues may obstruct patient travel to a clinic for appointments, with a 
resulting unwelcome delay in treatment. Some of these problems are gender related [10], while 
others require adaptations of (research) protocols to the local situation [11].  Women are more likely 
to be illiterate than men, and information given to the family may not always be shared with the 
patient. In many developing countries women cannot or are not permitted by cultural norms to 
travel by themselves, and therefore rely on a spouse or male family member to reach hospital. 
Alternatively, women can be treated at home, an approach that might also be of value for women in 
the developed world who at present have to visit a clinic for methotrexate injections four times 
within eight days, repeated each cycle. Considerable time and expense might be spared if injections 
could be given closer to home.  
Given the many different national laws and regulations, performing international studies is 
challenging and costly. However, by performing similar, concurrent studies in multiple countries 
and uniting the outcome of the various study sites this disadvantage can be partly counterbalanced 
[6,11,12]. Organizations such as the International Society for the Study of Trophoblastic Disease 
(ISSTD) could take the lead in organizing these collaborations. 
 
Collaboration is fun. 
Last but not least, while international collaborations in which experienced researchers support 
colleagues in less fortunate circumstances certainly present many challenges, these partnerships can 
also be both valuable and enjoyable. Collaboration improves local care, offers professional 
satisfaction and ultimately provides answers to shared scientific and clinical problems.  
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Abstract 
Background: Treatment of gynecologic cancers in young women is a real challenge as obtaining the future 
women’s fertility is almost always keened by the patient and her family. However, there are reported adverse 
outcome of pregnancy after treatment.  
Objective: To evaluate the obstetric outcome of patients who had undergone fertility preserving treatment 
for gynecologic premalignant and malignant diseases.  
Patients and methods: The study reviewed the pregnancy course and delivery data of 60 patients, who 
conceived after fertility sparing treatment for gynecologic premalignant and malignant diseases at 
department of Obstetrics and Gynecology and department of Clinical Oncology & Nuclear Medicine at 
Mansoura University Hospital from January 2012 to December 2015. We reported pregnancy complications, 
abnormalities during labor, neonatal outcome and any recurrence after delivery.  
Results: The mean age (± SD) of the studied patients was 24.9 (± 6.03) years. The median follow up was 13 
months (range: 1-40).The preceding lesions included gestational trophoblastic neoplasia (GTN), 43 cases 
(71.7%) while early ovarian carcinoma (14 cases, 23.3 %) and CIN III (2 cases, 3.3%) and micro-invasive 
cervical carcinoma (one case, 1.7%). All cases of GTN were treated with single or multiple agents’ 
chemotherapy. The 3 cases of cervical micro-invasive carcinoma and CIN III were treated with loop 
electrosurgical excision procedures (LEEP). Cases with stage 1a ovarian cancer were treated with unilateral 
salpingo-oophorectomy with peritoneal cytology and biopsy of the other ovary. Missed abortion was 
diagnosed in 4 cases (6.7%). The rate of caesarean delivery (CD) was high (70.9%). Intra-abdominal 
adhesions during CD were seen in (20.5%) of cases.  The neonatal outcome was normal in 53 cases, and 2 
cases (3.6%) of had congenital fetal malformations. The poor neonatal outcome was significantly correlated 
to number of chemotherapy cycles (P=0.04).  
Conclusion: The reproductive outcome after fertility preserving treatment of GTN, micro-invasive 
carcinoma of cervix, CINIII, and stage 1 ovarian cancer is comparable to those of general population. 
However, there were increased rate of CD, Intra-abdominal adhesions, missed abortion and congenital fetal 
malformations.     
Key words:  Gynecologic cancers; reproductive outcome. 
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Introduction 
Treatment of gynecologic cancers in young women represents actually a clinical challenge. 
Gynecological cancers occur variably at different ages, it may occur at younger age in 12 % of 
ovarian cancer, 5 % of endometrial cancer, and 2 % of cervix cancer [1].The preservation of the 
future fertility is usually requested by the patient and desired by her family. Gestational 
trophoblastic neoplasms (GTN) are well known tumors of reproductive age and mostly chemo-
sensitive. However, the rate of recurrent mole, a benign one of this group was reported in 2.5-9% of 
cases [2]. Gato and colleagues [3] studied the outcome of 50 patients who underwent fertility-
preserving treatment for choriocarcinoma, 23 conceived for a total of 43 pregnancies, meanwhile, 
congenital cardiac defects were observed in 2 of their neonates, namely, ventricular septal defect 
(VSD) and tetralogy of Fallot. 
On the other hand; some cases of cervical cancer occur before the age of 40 years where 
conservative surgery is to be applied. For these young patients with early stage of the disease, the 
loop electrosurgical excision procedures (LEEP) and conization provide a hope to preserve their 
fertilities [4]. Despite radical trachelectomy is considered as a more invasive surgical maneuver; 
some authors [5] reported in a study involving 210 cases, 35 had live births after this surgery. 
However, the rate of second trimester miscarriage and preterm labor was recorded to be higher than 
normal.  
Looking to ovarian cancer; conservative surgery remains the ideal for young patients with FIGO 
Stage I epithelial tumors and also for the borderline tumors [6, 7]. A systematic review carried by 
Darai et al [8] and concluded that conservative management of BOT resulted in a spontaneous 
pregnancy rate of 54% for early stage and 34% for advanced stage without increase of the risk of 
lethal recurrence. Some other authors [9, 10] reported that it is possible to maintain good 
reproductive function after conservative surgery for ovarian dysgerminoma followed by 
chemotherapy. Moreover, Vicus et al [11] studied the treatment outcome and reproductive function 
in women with ovarian immature teratoma and demonstrated the 6 of 11 patients conceived, 3 of 
them had received chemotherapy. 
To the best of our knowledge, there are few published studies in our locality about pregnancy and 
delivery criteria after fertility preserving treatment of premalignant and malignant gynecologic 
lesions. So, we conducted this retrospective study.                           
Patients and methods 
We reviewed in a retrospective descriptive manner the subsequent pregnancy and delivery data of 
60 patients who conceived after fertility sparing treatment of premalignant and early malignant 
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gynecologic diseases at the department of Obstetrics and Gynecology as well as department of 
Clinical Oncology, Mansoura University from January 2012 to December 2015. The study was 
approved by the Institutional Research Board (IRB) at Faculty of Medicine, Mansoura University. 
Patients included were those who had undergone fertility preserving treatment for premalignant and 
malignant gynecologic diseases, available for follow up during pregnancy and delivery after 
treatment and those who accept to participate in the study. We excluded patients with incomplete 
follow up data or inability to contact her or the treating physician.  
The data were retrospectively collected by checking the patients’ files at MUH and new data 
recorded by the managing physician outside. The initial criteria of the patient during admission as 
age, parity, medical condition, diagnosis and stage of the disease, surgical intervention if any, 
postoperative chemotherapy (type and number of courses) and follow-up data were preliminary 
registered. The data about subsequent pregnancy and delivery were collected by contacting the 
patient and her managing colleague at our center or at the private clinics where we reported 
pregnancy complications, type and abnormalities during labor, neonatal outcome and also any 
recurrence after delivery. All gathered data are then subjected to statistical analysis.  
Statistical analysis. 
All data collected were statistically analyzed by using SPSS for windows version 17.0 (SPSS, 
Chicago, IL). Continuous data were expressed as mean ± standard deviation (SD) and proportions 
for the socio-demographic characteristics. Multivariate analyses were performed where outcome of 
pregnancy was the dependent variable and number of cycles as well as interval between 
chemotherapy and pregnancy were independent variables. Mann-Whitney test and Kruskal-Wallis 
test were adopted to analyze the differences under different items. . P-value equal or <0.05 was set 
statistically significant. 
Results 
Sixty patients got pregnant after fertility preserving treatment of premalignant and malignant 
gynecologic lesions. The median follow up period was 13 months (range: 1-40).The mean age ± SD 
of our patients was set 24,9 ±  6,03 years meanwhile the median parity was 1.0 (range:1-4). The 
mean time interval from surgery or last cycle of chemotherapy till pregnancy ± SD was 14.47 (8.21) 
months and ranged from (1- 40) months. The predominant recorded lesions were gestational 
trophoblastic neoplasia (43 cases, 71.7%) followed by early ovarian carcinoma (14 cases, 23.3 %), 
lastly CIN III (2 cases, 3.3%) and micro-invasive cervical carcinoma (one case, 1.7%). The initial 
diagnosis and FIGO stage of the disease were presented and obviously all patients were in stage 1 
except for 2 cases with cervical intraepithelial neoplasia (CIN III), table (1). In addition; the same 
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table represented the fertility preserving treatment of the studied cases. Low-risk GTN cases were 
treated with methotrexate (50 mg/kg body weight) alternating with folinic acid (0.1mg/kg) but 5 
cases failed to respond, so they received multiple agent chemotherapy (EMACO) together with one 
case of high-risk GTN. Three cases of cervical microinvasive carcinoma and CIN III were treated 
with LEEP. Furthermore, cases with stage 1a ovarian cancer were treated with unilateral salpingo-
oophorectomy with peritoneal cytology and biopsy of other ovary. Three cycles of adjuvant 
chemotherapy (Carboplatin-Paclitaxel) were added to patients with stage 1c epithelial tumors and 4 
cycles of (Bleomycin-Etoposide-Cisplatinum) for stage 1c germ cell tumors. 
 
Table (1) : Patients’ demographic data. 
Variable  Total number (60) 
Age in years (mean & SD) 24.92 (6.03) 
Parity (median & range) 1.0 (1 - 4) 
Mean interval from treatment 
to pregnancy in months (SD) 
14.47 (8.21)          Range: (1-40) months 
Type of tumor: Number (%) FIGO stage Treatment offered 
Surgery Chemotherapy 
1. GTN 
2. Ovarain: 
Borderline tumors  
Serous cystadenocarcinoma 
 
Mucinous 
cystadenocarcinoma 
 
Immature teratoma 
 
 
Mixed GCT 
 
Dysgerminoma 
    Granulose CT 
 
 
3. Cervical carcinoma 
 
4. CIN III 
43 (71.7) 
 
1 (1.7) 
5 (8.3) 
 
2 (3.3) 
 
2 (3.3) 
 
 
1 (1.7) 
 
1 (1.7) 
2 (3.3) 
 
1 (1.7) 
2 (3.3) 
1 (43 cases) 
 
1a (1 case) 
1a (3 cases) 
1c (2 cases) 
1a (1 case) 
1c (1 case) 
1a (1 case) 
1c (1 case) 
 
1c 
 
1a (1 case) 
1a (2 cases) 
 
 
 
1a1 (1 case) 
 
0 (2 cases) 
No 
 
 
USO 
USO 
USO 
USO 
USO 
USO 
USO 
 
 
USO 
 
USO 
USO 
 
LEEP 
 
LEEP 
Methotrexate (37), 
EMA/CO (6) 
 
No 
No 
Carboplatin-Paclitaxel 
No 
Carboplatin-Paclitaxel 
No 
BEP 
 
 
BEP 
 
No 
No 
 
No 
 
No 
Mean cycles of 
chemotherapy(SD)  
4.15 (2.08) 
Abbreviations: USO; unilateral salpingoopherectomy, LEEP; loop electrosurgical procedure, EMACO; 
Etoposide, Methotrexate, Adriamycine, Cyclophosphamide, and Vincristine, BEP; Bleomycin, Etoposide 
and Cisplatinum. 
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Table [2]: Pregnancy and labor courses among the studied cases 
Variable  Number   (%) 
Pregnancy course: (n=60) 
FTNP  
PIH 
Preterm pregnancy 
Missed abortion 
Induced abortion  
 
51      (85%)  
1        (1.7%) 
3        (5%)  
4        (6.6%) 
1        (1.7%) 
Labor course:  (n=55) 
VD  
CD  
Findings during CD:  (n=39) 
-Intraoperative adhesions 
-Congested uterus 
-Thin uterine wall  
-Caesarean hysterectomy 
 
16      (29.1) 
39      (70.9) 
 
8        (20.5%) 
2        (5.1%) 
1        (2.6%) 
2        (5.1%) 
Neonatal outcome:  (n=55) 
Normal 
CFMF  
 
53      (96.4%) 
2        (3.6%) 
Recurrence after delivery: 1        (1.7%) 
Abbreviations: FTNP; full term normal pregnancy, PIH; pregnancy induced hypertension, VD; vaginal 
delivery, CD; cesarean delivery, CFMF; congenital fetal malformation.  
 
Table [3]. Correlation of missed abortion and neonatal outcome to chemotherapy. 
 Pregnancy 
Normal        Missed abortion 
P value Neonate 
Normal         CFMF 
P value 
1.Number of cycles 
    Median (range) 
4(1-10)                5(2-6) 0.17 
 
4(1-9)              8(6-10) 0.04 
2.Interval* 
   Median (range) 
13(1-40)                9(3-13) 0.049 13(1-36)        13(8-18) 0.23 
Interval*: From surgery or last cycle of chemotherapy till pregnancy. 
Small number of cases in adverse pregnancy and neonatal outcome might result in statistical inaccuracy. 
 
The pregnancy outcome was presented in table (2). There were 3 cases (5%) of preterm labor at 36 
weeks, none of them needed incubator care, 2 of them had performed LEEP whilst one after 
treatment of GTN. There were 4 cases of missed abortion (6.7%), 3 of them were after 
chemotherapy, and a case of induced abortion (due to short interval between chemotherapy and 
pregnancy). The occurrence of missed abortion was significantly correlated to shorter interval 
between chemotherapy and pregnancy (P = 0.049). No reported maternal complications during 
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pregnancy except for pregnancy-induced hypertension in one case. Regarding delivery; 55 cases 
were delivered, 39 (70.9%) delivered by caesarean delivery (CD) and 16 (29.1%) delivered 
vaginally. Two cases of ovarian tumors (stage 1c) performed total abdominal hysterectomy and 
salpingo-oophorectomy with surgical staging during CD under request of the patients. However, 
there was no evidence of disease recurrence after histopathological examination of their specimens. 
During caesarean delivery, 8 of 39 cases (20.5%) had adhesions between the uterus and intestine. 
Seven of them had undergone conservative surgery for ovarian cancer and one case received 
combination chemotherapy for GTN. Two of 39 cases (5.1%) had congested uterine wall with 
edema and tearing of the stitches. One case received single whereas the other received combination 
chemotherapy. Furthermore, one case (2.6%) previously treated choriocarcinoma with combination 
chemotherapy; the fundus of the uterus was found to be thin which probably the site of the initial 
tumor. Biopsies from the other ovary, adhesions, omentum, and peritoneum were taken during CD 
and proved free (Table 2). The neonatal outcome was normal in 53 cases, and 2 cases (3.6%) had 
congenital fetal malformation (both received chemotherapy).One case of them had congenital 
intestinal obstruction (received 10 courses of methotrexate) and the other case of ventricular septal 
defect (received 6 courses of EMACO). The poor neonatal outcome was significantly correlated to 
number of chemotherapy cycles (P=0.04).However, neonatal outcome was not correlated to interval 
between pregnancy and chemotherapy (P=0.2) (table 3). No reported cases of recurrence after 
treatment of cervical and ovarian lesions in our study. Only one case of GTN recurrence was 
reported after one month of delivery (1.7%). She was presented by secondary postpartum 
hemorrhage and received EMACO protocol (table 2). 
Discussion 
During the decision making for gynecologic cancer, the tumor board usually faces a challenge 
between the both oncological and reproductive outcomes. This particularly occurs when the 
gynecologic cancer patient is at young age and needs a future pregnancy. This raised our attention 
for retrospective analysis of 60 patients who conceived after fertility preserving treatment for GTN, 
microinvasive cervical carcinoma, CIN III, and early ovarian cancer. 
It is well known that, the prognosis of GTN after fertility sparing treatment is excellent as the tumor 
is chemosensitive. Single agent Methotrexate is used as first line for low risk cases and EMACO is 
the commonly used second-line combination chemotherapy protocol [12,13]. We reported that 
pregnancy following chemotherapy resulted in 4 missed abortions (6.7%) and one case of induced 
abortion. The adverse pregnancy outcome for patients was not correlated to number of 
chemotherapy cycles (P=0.17) but was significantly correlated to the shorter interval between the 
last chemotherapy and pregnancy (P=0.049). The miscarriage after chemotherapy was also reported 
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by Gadducci et al [14].The long term effect of chemotherapy on obstetric outcome is unclear and 
needs to be evaluated in a large prospective study. Moreover, one case developed recurrence one 
month after delivery which necessitated continuing postpartum surveillance of the cured patients. 
In our study 3 cases had undergone LEEP procedure for treatment of CIN III and microinvasive 
carcinoma, however 2 of them developed preterm labor. The association between LEEP and 
preterm births was also proved by Bjorge et al [15].The oncological and reproductive outcome of 
the managed 14 cases of early ovarian cancer were relatively excellent as the authors did not report 
any case of recurrence during the follow up period and with a satisfactory neonatal outcome even 
after receiving adjuvant chemotherapy, this comes similar to results found by many other authors 
[6-10]. 
The mode of delivery of the studied cases was CS in 39 (70.9%) which is considered a very high 
figure compared to the reported national figures (22%) [16].The high rate of CS may be attributed 
to the concept of the treating physician to perform “second-look” during CS or request of the patient 
due to fear of limited fertility after surgery and chemotherapy. However, this explanation was not 
supported by other authors.      
Regarding the neonatal outcome in our study, we reported 2 cases (3.6%) of congenital fetal 
malformation (both received chemotherapy). This rate is higher than general population which 
reported to be 2.4% [17]. The poor neonatal outcome was significantly correlated to the number of 
chemotherapy cycles (P=0.04) (table 3).This finding is supported by some other study done by Gato 
et el [3] who reported that total dose of methotrexate was higher in patients who delivered a child 
with cardiac anomaly. However, our finding did not agree with Gadducci et al [18] who reported 
that there was no increase of risk of CFMF after chemotherapy for GTN. This disagreement may be 
due to small sample size of our study.   
One limitation of this study is lack of data about the total number of cases who had underwent 
fertility preserving treatment during the study period, so we could not estimate the ratio of 
pregnancy among the patients who had received the same treatment. Small number of cases with 
cervical lesions as well as adverse pregnancy and neonatal outcome might result in statistical 
confusion. Lastly; the authors also recommend a multicenter not a single center study, like ours, for 
the results to be more clarified and satisfactory.   
Conclusion 
Fertility-sparing treatment is a viable tool to enable gynecological cancer patients of young age to 
fulfill their family building without impairment of oncological outcome and the reproductive 
outcome of GTN, micro-invasive carcinoma of cervix, CINIII and stage 1 ovarian cancer is 
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comparable to those of general population but with increased rate of CD, Intra-abdominal 
adhesions, missed abortion and congenital fetal malformations.     
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Abstract 
Objective: To determine the prevalence of GTD in the referred specimens of uterine evacuation after 
miscarriage, in clinically diagnosed molar pregnancies, and post-abortive bleeding. 
Methods: The referred clinical reports to Pathology department of Mansoura University& private practice 
settings and their corresponding histopathologic diagnoses during the period from 1/1/2009 to 31/3/2014 
were reviewed. 
Results: The study included 640 referred specimens of contents of uterine evacuation. The mean age of the 
cases was 26.5 years (range: 15.0-54.0 years). The mean GA was 10.3 weeks (range: 5.0-19.0 weeks).The 
commonest clinical diagnosis of the referred cases was missed abortion (329 cases, 51.4%). Molar pregnancy 
was diagnosed histologically in 103 of 499 referred cases as miscarriage (20.6%). Histopathological 
examination of specimens of uterine curettage due to post-abortive bleeding revealed GTN in 12 of 27 cases 
(44.4%). 
Conclusion: Molar pregnancy was diagnosed histologically in 20.6% of the referred cases as various types 
of miscarriage. We recommend histopathologic examination of uterine contents after pregnancy termination 
and post-abortive bleeding. Further studies are needed to confirm this high prevalence of molar pregnancy in 
our locality. 
Key Words: Miscarriage; Pathology; Molar pregnancy. 
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Introduction. 
Gestational trophoblastic disease (GTD) includes several disease processes that originate in the 
placenta. Under the WHO classification, gestational trophoblastic disease includes hydatidiform 
mole, invasive mole, choriocarcinoma, placental site trophoblastic tumors, and epithelioid 
trophoblastic tumors [1]. The majority of both complete and partial hydatidiform moles present as 
early pregnancy failure with or without vaginal bleeding [2]. This mimics miscarriage, the most 
common complication of pregnancy, occurring in 15-20% of all pregnancies [3]. Not all women 
with a miscarriage will consult a gynecologist, or undergo ultrasonography. Even when women visit 
a gynecologist because of symptom of bleeding in early pregnancy the diagnosis of a molar 
pregnancy can be missed by clinical and ultrasound examination. Fowler et al [4] concluded from 
their large retrospective study that routine pre-evacuation ultrasound examination identified less 
than 50% of hydatidiform moles. Detection rates in their study were higher for complete compared 
to partial moles.  
Routine histopathologic assessment of products of first-trimester miscarriages may therefore 
diagnose important pathologies such as molar pregnancy and placental site trophoblastic disease 
[5]. But in many cases, histopathological examination of the products of conception is not 
performed.  
Post molar GTD was reported to occur in 7.5-20% of patients after evacuation of complete 
hydatidiform moles and in 2.5-7.5% following evacuation of partial moles. The vast majority of 
cases occur during the first 6 months after molar evacuation [6]. 
There is worldwide geographic variation in incidence of GTD. The incidence of molar pregnancy in 
southeast Asia was reported to be 1-12 per 1000 pregnancies which is 7-10 times higher than that in 
Europe or North America where it is reported to be 0.5-1 per 1000 pregnancies [7,8,9].In Africa, the 
incidence of molar pregnancy and choriocarcinoma was 1.2 and 0.5 per 1000  deliveries, 
respectively [10]. 
The aim of this retrospective study is to determine the prevalence of GTD in the referred specimens 
of uterine evacuation after miscarriage, in clinically diagnosed molar pregnancies, and   post-
abortive bleeding. 
Patients and Methods. 
This retrospective study was performed in the department of Pathology and department of 
Obstetrics and Gynecology, Mansoura University as well as private practice settings. The referred 
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clinical reports and their corresponding histopathologic diagnoses in the period from 1/1/2009 to 
31/3/2014 were reviewed. 
The clinical data were collected from the referral letters (age, gestational age, and ultrasound 
diagnosis). Histopathological diagnoses were obtained by an expert gynecologic pathology team 
after hematoxylen and eosin staining. In doubtful cases, the diagnoses were confirmed by 
immunohistochemical staining.  
Inclusion criteria.  
 Referred specimens of products of uterine evacuation with a gestational age of 19 weeks or less 
(spontaneous, missed, and incomplete miscarriage), referred specimens as products of uterine 
evacuation of clinicaly (and by ultrasound) diagnosed molar pregnancy, and post-abortive bleeding 
in which initial specimens of miscarriage were not examined. 
Exclusion criteria. 
 Cases with miscarriage who were managed by expectant treatment with no available specimens and 
referred cases that were clinically diagnosed as ectopic pregnancy. 
The histopathologic diagnosis was compared to the clinical (including ultrasound) diagnosis as 
stated by the gynaecologist who referred the patient. Hospital files were retrieved for cases with 
histopathologic diagnosis GTD, to obtain all clinical and follow up data. 
Statistical analysis.  
Data was analyzed using SPSS (Statistical Package for Social Sciences) version 15. Qualitative data 
was presented as number and percent. Comparison between groups was done by Chi-Square test. 
Quantitative data was presented as mean ± SD.  P < 0.05 was considered to be statistically 
significant. 
Results 
The study included 640 referred specimens of contents of uterine evacuation after early pregnancy 
loss, clinically diagnosed molar pregnancies, and post-abortive bleeding. The mean age of the cases 
was 26.5 years (range: 15.0-54.0 years). Gestational age (GA) was available in 613 cases. The mean 
GA was 10.3 weeks (range: 5.0-19.0 weeks). 
The commonest clinical diagnosis of the referred cases was missed abortion (329 cases, 51.4%). 
Molar pregnancies, spontaneous abortion, incomplete abortion and post abortive bleeding 
represented 114 cases (17.8%), 96 cases (15%), 74 cases (11.6%), and 27 cases (4.2%) respectively.   
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Table 1 summarizes the correlation of the clinical diagnosis to the histopathological diagnoses of 
the referred cases. There were 499 cases referred to the pathologist as various types of miscarriage 
(missed, incomplete, and spontaneous miscarriage), the pathologic diagnoses of these cases 
revealed that 103 of them (20.6%) were complete or partial mole.  
Table 1. Histopathological diagnoses of uterine contents in different clinical types of 
abortions. 
 Products 
of 
conception 
Decidual 
reaction&IER* 
Partial 
mole 
Complete 
mole 
Other GTD 
 
Total 
Missed 
abortion** 
221 
(67.2%) 
39(11.9%) 65 (19.8% ) 4(1.2% ) 0 329 
Incomplete 
abortion 
45(60.8%) 13(17.6% ) 5 (6.8%) 10(13.5%) 1 (1.4%), CC# 74 
Spontaneous 
abortion 
63(65.6%) 14 (14.6%) 13(13.6% ) 6( 6.3%) 0 96 
Molar 
pregnancy 
12(10.5%) 1(0.9%) 37(32.5%) 64(56.1%) 0 114 
Post 
abortive 
bleeding 
 
9(33.3%) 
 
6(22.2%) 
 
0 
 
4(14.8%) 
8(29.6%), 
5 cases of CC# 
2 cases of PSTT## 
1 case of invasive mole 
 
27 
Total 350 73 120 88 9 640 
IER*: Irregular endometrial response. 
Missed abortion**: including recurrent missed abortion. CC#: choriocacinoma. 
PSTT##:   placental site trophoblastic tumor 
Table (2) Correlation of the age of the patient to development of GTN. 
Age group Non GTN GTN Total 
<20y 101 16 (13.7%) 117 
20-30y 371 13 (3.4%) 384 
30-40y 107 7 (6.1%) 114 
>40y 18 7 (28%) 25 
Total 597 43 640 
Chi-Square Tests 
 Value Asymp. Sig. (2-sided) 
Pearson Chi-Square 33.968 0.0001 
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As can be seen from table 1; the clinical and ultrasound diagnosis “molar pregnancy” was 
confirmed pathologically in 101 of 114 cases (88.6%). In the other 13 cases (11.4%) the clinical 
diagnosis molar pregnancy was not confirmed by histopathology. 
Post-abortive bleeding represented 27 (4.2%) of the referred cases, 12 of them (44.4%) were found 
to be GTD, including five cases of choriocarcinoma, two cases of PSTT, one case of invasive mole, 
and four cases of vesicular mole (table 1). For none of the 27 cases, histopathological examination 
of products of conception was performed at the time of miscarriage. Uterine curettage was 
performed 7- 42 days thereafter.  
The progression to GTN was significantly correlated to the extremes of the reproductive age of the 
patient (P < 0.0001). The correlation of age of the patient to development of post-molar GTN is 
represented in table 2.   
 
Discussion 
It is often difficult to differentiate between retained products of conception and GTD solely on the 
basis of clinical criteria. Furthermore, the sonographic appearance of products of conception can 
share similar imaging findings with early GTD [11]. Histopathological examination of products of 
conception remains the current gold standard for the detection of gestational trophoblastic diseases 
[4,12,13].  
The study included 640 referred specimens of contents of uterine evacuation after early pregnancy 
termination and post-abortive bleeding. The histopathological diagnoses were correlated to the pre-
evacuation clinical and ultrasound data as supplied to the pathologists through the referred clinical 
reports. 
Partial and complete molar pregnancies were diagnosed histologically in 103 of 499 referred cases 
as products of uterine evacuation of miscarriage (20.6%). This figure is much higher than reported 
by Tasci et al [2] who reported that by histopathologic examination of products of conception 
partial hydatidiform mole was diagnosed in 2.1%, complete hydatidiform mole in  0.43% and 
placental site trophoblastic tumor was detected in 0.12%. This discrepancy may be due to larger 
sample size of their study (1606 cases versus 499 cases in our series).Other explanation of 
overestimation of molar pregnancy in our study that we only included cases who referred for 
histopathological assessment and not all cases of miscarriage. A third reason is the different 
incidence of GTD with different geographic distribution. 
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The histopathological examination confirmed the pre-evacuation clinical and ultrasound diagnosis 
of molar pregnancy in101 of 114 cases (88.6%). Again, this figure is higher than reported by 
Fowler et al [4], who reported that routine pre-evacuation ultrasound examination identified less 
than 50% of hydatidiform moles. The difference in our figures may be due to the selection bias; our 
center is a tertiary referral center and including the high number of patients with clinical molar 
pregnancy influenced this percentage. 
Molar pregnancy was more common in extremes of reproductive age in our cases (P < 0.0001), this 
finding was also reported by Bracken [14].  
Histopathological examination of specimens of uterine curettage in cases of post-abortive bleeding 
diagnosed 12 of them (44.4%) as GTD. The high incidence of GTD among studied cases with post-
abortive bleeding arouses the importance of mandatory histological examination of uterine contents 
of this group of patients. To the best of our knowledge; this finding was not reported by other 
authors. 
There is no doubt that many cases of pregnancy termination in our locality were not subjected to 
histopathological examination. The authors tried to investigate for the cause. The most important 
cause was that the clinician was satisfied with his /or her clinical and ultrasound diagnosis. Other 
causes were presentation of some patients with emergency vaginal bleeding and non-availability of 
pathology laboratories in the rural areas. Furthermore, expectant management of miscarriage 
decreased the chance of specimen examination because in most cases the products of conception 
were expelled at home. Expectant management of miscarriage was recommended by many authors 
[15,16,17].  
Although ideally all specimens removed should be assessed by histopathology, routine assessment 
of miscarriage will be costly and time consuming. We should at least try to identify those cases that 
are at risk of gestational trophoblastic disease; as women in the extremes of reproductive age, 
women with remarkable findings on ultrasound, and women with recurrent miscarriage.   
The limitations of this study are scanty clinical data in the referred clinical reports and its inclusion 
only cases that referred for histopathological assessment and not all cases of miscarriage and post-
abortive bleeding which overestimated the prevalence of GTD in the studied cases.  
Conclusion 
Unsuspected molar pregnancy was diagnosed histologically in 103 of 499 referred cases as 
miscarriage (20.6%). Histopathological examination of specimens of uterine curettage due to post-
abortive bleeding revealed GTD in 44.4% of cases. We recommend histopathologic examination of 
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uterine contents after pregnancy termination and post-abortive bleeding. Further studies are needed 
to confirm this high prevalence of molar pregnancy in Egypt. 
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Abstract 
Background: Although the morphological features characteristic of products of conception specimens 
including molar pregnancies are well described, substantial histopathological similarities are observed 
between the different entities, especially in cases of early pregnancies. Furthermore, there are no current 
solid criteria that could predict cases with progression to persistent gestational trophoblastic disease. In this 
study, we aimed to determine the most specific histopathological and immunohistochemical features required 
for accurate diagnosis that can reliably predict the clinical behavior.  
 
Methods: Sixty-five cases of products of conception were reviewed clinically and pathologically, and any 
progression to persistent gestational trophoblastic disease (PGTD), if present, was noted. Pathological 
assessment of the archival material included re-cut sections of 5 μm in thickness, routine staining with 
hematoxylin and eosin and immunohistochemical staining of p57Kip2.  
 
Results: Certain histopathological criteria were found to be significant in differentiation between complete 
hydatidiform mole (CHM) and partial hydatidiform mole including villous shape and outline, villous 
trophoblast hyperplasia, and atypia in extravillous trophoblasts. There were no significant differences in any 
morphological or immunohistochemical features between cases with or without subsequent development of 
GTD.  
Conclusions: Histopathological diagnosis of molar pregnancy remains problematic especially in early 
gestation. Their diagnosis should be stated after a constellation of specific histopathological criteria in order 
not to miss CHM. p57Kip2 immunohistochemistry is of great value in diagnosis of cases that had equivocal 
morphology by histopathological examination. However, there were no significant features to predict cases 
that subsequently developed persistent GTD. 
 
Key Words: Hydatidiform mole; Complete hydatidiform mole, early; p57Kip2 immunohistochemistry 
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Introduction  
Hydatidiform mole (HM) is an abnormal gestation characterized by significant hydropic change and 
variable trophoblastic proliferation involving part or all of chorionic villi [1,2]. HM is categorized 
into two separate entities, complete hydatidiform mole (CHM) and partial hydatidiform mole 
(PHM), according to morphology and cytogenetics. However, hydropic abortion (HA) could 
morphologically mimic HM [3,4]. 
Characteristic morphologic features have been proposed for the diagnosis of product of conception 
(POC) specimens including CHM, PHM, and HA. However, substantial histopathological 
similarities are observed between the three entities, especially in cases of early detection resulting in 
interobserver and intraobserver variability in the diagnosis of products of conception (POC) 
specimens [5,6]. Thus, the diagnosis of POC on the basis of histopathology alone remains a 
challenge for pathologists, even those experienced [7]. 
Persistent gestational trophoblastic disease (PGTD) develops after CHM in 10% to 30% of cases,[4] 
and after PHM in 0.5% to 5% whereas HA has no relation to PGTD [5]. Thus, follow-up serum β-
human chorionic gonadotropin (β-HCG) measurements aren’t essential in cases of HA, whereas 
these measurements form part of surveillance for PGTD in cases of HM. Therefore, accurate 
distinction of CHM from PHM on one hand and of HM from HA on the other hand is important for 
appropriate clinical management and has prognostic implications [3]. 
Difficult cases may require molecular techniques using the differences in DNA content of different 
POC cases [8]. However, such molecular diagnostic methods are technically difficult, relatively 
costly, and non-available in most of pathology laboratories [2]. Detection of the expression of gene 
products such as p57Kip2 by the trophoblastic cells should be highlighted. The p57Kip2 gene 
(CDKN1C) is a strongly paternally imprinted gene expressed only by the maternal allele in most 
tissues and is involved in implantation [9]. In normal placenta, nuclear p57Kip2 expression is seen 
in villous cytotrophoblast, extravillous trophoblast, villous stromal cells, and deciduas [10,11]. 
p57Kip2 can identify CHM (androgenetic diploidy) by the lack of its expression12-14 and can be 
helpful in distinguishing CHM from PHM and non molar HA,11 but can’t distinguish PHM 
(diandric monogynic triploidy) from nonmolar (biparental diploidy) specimens as both are positive 
[14]. CHM mostly doesn’t contain maternal genome. Therefore, p57Kip2 staining is unexpressed or 
greatly reduced in the nuclei of their cytotrophoblasts and stromal cells [11]. Products of conception 
containing maternal genetic material, PHM and nonmolar HA, show positive nuclear p57Kip2 
staining in cytotrophoblast and villous stromal cells. p57Kip2 is also expressed in intermediate 
trophoblast islands and decidual cells, serving as positive internal control in all POC cases [12,13]. 
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In this study, we aimed to define precise histopathological and immunohistochemical features to 
make a proper diagnosis of the different types of HMs especially in early gestational ages and to 
distinguish those from other mimics. Furthermore, specific features to predict prognosis and 
progression to PGTD were investigated. 
 
Materials and Methods 
Sample collection 
Archival materials of sixty five cases of POC specimens were retrieved from the department of 
Pathology, Faculty of Medicine, Mansoura University, between January 2013 and December 2014. 
The protocol was approved by the Ethical Committee of Mansoura University and informed 
consents were obtained from the patients. 
Histopathological review 
The paraffin blocks were re-cut in 5-μm-thick sections and stained with hematoxylin and eosin stain 
and were independently reviewed by two pathologists for evaluation of the main morphological 
findings of HM.[13,15] 
Immunohistochemistry 
Five-micrometer-thick tissue section from each case was subject to immunohistochemical staining 
using monoclonal antibody against the p57Kip2 protein (NeoMarkers/Lab Vision Corpora- tion, 
Fremont, CA, USA) with dilution 1:200 and the Envision system (DakoCytomation, Glostrup, 
Denmark). All the steps were performed according to the manufacturers’ instructions. 
In all cases, p57Kip2 was assessed in the nuclei of the villous cytotrophoblasts, extravillous 
trophoblasts, and villous stromal cells. Specimens were interpreted as positive for p57Kip2 staining 
when there was distinct nuclear staining of villous cytotropho-blasts and stromal cells. The p57Kip2 
stain was interpreted as negative when there was no distinct staining or limited nuclear staining (< 
10%) of villous cytotrophoblasts and stromal cells. Staining of intermediate trophoblasts and/or 
maternal decidua was considered as the positive internal control for these specimens. 
Statistical methods 
Data were analyzed using the program SPSS ver. 20 (IBM Corp., Armonk, NY, USA) to obtain 
descriptive statistics. Statistical significance was determined at 95% level of confidence (i.e., 
differences will be considered significant if p<0.05). 
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Results 
Examination of clinical data 
The age of patients ranged from 16 to 50 years with a mean of 26 ± 8 years and a median of 24 
years. All cases were in the first or early second trimester. Their gestational age ranged from 6 to 14 
weeks with a mean of 9±2 weeks and a median of 8 weeks. 
Histopathological examination 
Significant histopathological criteria for the diagnosis and distinguishing different entities are 
shown in Table 1. Examples of the morphological features are demonstrated in fig. 1. 
Immunohistochemistry 
Specimens that showed distinct nuclear staining of cytotrophoblasts and villous stromal cells were 
interpreted as positive for p57Kip2 (Fig. 1H). On the other hand, specimens that showed no or 
limited nuclear staining (in < 10%) of cytotrophoblasts and villous stromal cells with positive 
internal control were considered negative for p57Kip2 stain (Fig. 1). Accordingly, the studied cases 
were redistributed as shown in table 2. 
CHM originally constituted 39 cases. However, after reevaluation based on the histopathological 
criteria and p57Kip2 immunohistochemistry, seven cases were added to CHM (previously 
diagnosed as PHM). On the other hand, one case originally diagnosed as CHM was converted to 
PHM. The final typing of the molar cases was, therefore, 45 cases of CHM and 11 cases of PHM. 
Table 1. Significant histopathological criteria according to the final diagnosis of the studied cases using p57Kip2 
immunohistochemistry 
Significant criteria differentiating between 
CHM and PHM 
Significant criteria differentiating between molar 
and nonmolar pregnancy 
Villous shape and outline: p < .001 Villous shape and outline: p < .001 
Villous trophoblast hyperplasia: p = .001 Cistern formation: p < .001 
Atypia at extravillous trophoblast: p < .001 Trophophoblastic inclusion: p = .001 
 Villous trophoblast hyperplasia: p < .001 
CHM, complete hydatidiform mole; PHM, partial hydatidiform mole. 
Table 2. Comparison of the diagnosis of the studied cases by his- topathological examination and p57Kip2 
immunohistochemistry (n = 56) 
 Case p-value 
Method of diagnosis CHM PHM 
Haematoxylin and eosin stain 39 (60) 17 (26) < .001 
p57Kip2 immunohistochemistry 45 (69) 11 (17)  
Values are presented as number (%). 
CHM, complete hydatidiform mole; PHM, partial hydatidiform mole. 
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Follow-up 
By following the clinical history of all studied cases, nine cases (14% of total/16% of molar cases) 
were found to progress into gestational trophoblastic disease (GTD) based on persistence of 
symptoms and serum β-HCG level (table 3). These represented 18% of CHM and 9% of PHM 
cases. As shown in Table 4, his-topathological criteria of these cases were examined and compared 
with the results of p57Kip2 immunohistochemistry to detect the most statistically significant 
histopathological feature that can predict the progression of molar disease into PGTD. According to 
the current study, none of the studied histopathological parameters could differentiate between 
cases with or without progression to GTD. 
 
Fig. 1. (A) Complete hydatidiform mole (CHM): irregular villous outline (club shaped) with villous stromal 
karyorrhectic debris. (B) Partial hydatidiform mole (PHM). Two villous populations; large edematous villi 
with irregular outline and normal appearing nondistended ones. (C) Hydropic abortion (HA): distended villi 
with hydropic change. (D) CHM: trophoblastic inclusion (arrow). (E) CHM: cistern formation. (F) CHM: 
multifocal villous trophoblastic hyperplasia. (G) HA: positive p57Kip2 nuclear staining in intermediate 
trophoblast as positive internal control (asterisk). Positive p57Kip2 nuclear staining in villous 
cytotrophoblasts (CT) (short arrow) and villous stromal cells (long arrow) (immunoperoxidase). (H) CHM 
p57Kip2 immunohistochemistry: negative nuclear staining in villous CT (short arrow) and villous stromal 
cells (long arrow); positive p57Kip2 nuclear staining in intermediate trophoblast as positive internal 
control (asterisk) (immunoperoxidase). (I) PHM: positive p57Kip2 nuclear staining in villous CT 
(short arrow) and villous stromal cells (long arrow) (immunoperoxidase). 
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Table 3. Cases that developed gestational trophoblastic neoplasia (n = 9) 
Case Age 
(yr) 
GA 
(wk) 
Histopathology p57Kip2 β-HCG 
(mIU/mL) 
MTX Response Second-line 
treatment 
1 20 10 CHM Negative 2907 2 Yes - 
2 28 4 CHM Negative 1294 2 Yes - 
3 29 8 CHM Negative 280 1 Yes - 
4 48 8 CHM Negative 1328 3 No Hysterectomy 
5 20 12 CHM Negative 4177 3 Yes - 
6 29 9 CHM Negative 446 2 Yes - 
7 19 8 CHM Negative 3260 2 Yes - 
8 42 10 CHM Negative 5000 6 No EMA/CO 
9 24 8 PHM Positive 4990 5 Yes - 
GA, gestational age; β-HCG, β-human chorionic gonadotropin; MTX, methotrexate; CHM, complete 
hydatidiform mole; EMA/CO, etoposide, methotrexate, actinomycin D, cyclophosphamide, 
vincristine/oncovine; PHM, partial hydatidiform mole. 
 
Table 4. Histopathological criteria of cases that clinically progressed to PGTD in comparison 
to the rest of the series 
Parameters  PGTD 
(n = 9) 
Non-PGTD 
(n = 56) 
p-
value 
Villous shape and outline Distended regular 1 9 > .99 
 Distended irregular 5 24  
 Non-distended 1 8  
 Two population of villi   
(distended and non-distended) 
2 15  
Cistern Present 8 45 > .99 
 Absent 1 11  
Trophoblastic inclusion Present 6 34 > .99 
 Absent 3 22  
Stromal myxoid change Present 4 26 > .99 
 Absent 5 30  
Villous trophoblast hyperplasia Circumferential 4 21 > .99 
 Multifocal 4 27  
 Polar 1 8  
Stromal karyorrhexis Present 0 14 .186 
 Absent 9 42  
Atypia at extravillous trophoblast Mild 5 32 > .99 
 Marked 4 24  
PGTD, persistent gestational trophoblastic disease. 
 
Discussion 
The present study was performed to investigate histopathological parameters commonly used 
during routine histopathological examination in the differential diagnosis of POC cases, especially 
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those with early gestational age. Also, we aimed to study the value of using these histopathological 
criteria for diagnosis of HM specimens by comparing them with the results of p57Kip2 
immunohistochemical staining. 
In agreement with previous reports, our results showed that examination of the villous shape was 
statistically significant in differentiation between CHM and PHM cases on one hand and between 
molar and nonmolar cases on the other hand [16,17]. Most of our studied CHM cases (62%) had a 
population of distended villi with irregular outline. This was significant in differentiation between 
POC specimens and in favor of early CHM [15,18]. Our  results were in contrast with the results of 
the study by Ishikawa et al [16] who found that enlarged villi with regular round outline was a good 
marker for the diagnosis of CHM. This disagreement can be explained by the fact that the 
gestational age of our cases was in the first trimester, and at this early gestational age, villi of CHM 
don’t exhibit the well formed distended villi with regular outline and have more irregular outline. 
Cistern formation is a major criterion in HM. Our study showed that cistern formation was found in 
CHM (96%) more common than in PHM cases (91%). It was significant in differentiation between 
molar and nonmolar pregnancy. On the other hand, it wasn’t significant in differentiation between 
the CHM and PHM. This is in contrast to other studies that found it significant and in favor of 
diagnosis of PHM [17,18]. This may be because of the difference in number of studied CHM cases. 
We found that the presence of trophoblastic inclusion in the villous core was present in 82% of 
PHM and in 67% of CHM. This was statistically significant in differentiation between cases of 
molar and nonmolar pregnancy but was insignificant in differentiation between the CHM and PHM 
as described in previous reports [16,17,19]. Trophoblastic hyperplasia is an essential requirement 
for the diagnosis of molar pregnancy [20]. The results of this study demonstrated that 59% of CHM 
cases had circumferential villous trophoblastic hyperplasia, while 88% of PHM cases exhibited 
multifocal villous trophoblast hyperplasia. Polar trophoblast hyperplasia was in favor of nonmolar 
POC diagnosis. It was found to be statistically significant in differentiation between CHM and 
PHM on one hand and between molar and nonmolar POC on the other hand, in agreement with 
previous studies [19,20]. On the other hand, our results disagreed with the study of Abdou et al [17] 
on 59 cases of POC specimens and found that trophoblast hyperplasia had no statistically significant 
value in that differentiation. This marked circumferential villous trophoblast hyperplasia which was 
found in CHM cases may be related to the absence of p57Kip2 expression by the villous 
cytotrophoblasts and villous stromal cells in CHM cases which lack the maternal genome. This 
results in loss of cell cycle control and hence increased trophoblast proliferation. 
It is known that villi in CHM have a high level of stromal karyorrhectic debris [21].  In this study, 
villous stromal karyorrhectic debris wasn’t observed in any case diagnosed as PHM or nonmolar 
Ch. 8 │  Expression of p57Kip2 in Early Molar Pregnancies  
 
 
 
 
 
 
 
94 
POC. Although the villous stromal karyorrhectic debris was found in 36% of CHM cases, it wasn’t 
statistically significant in differentiation of the three entities; CHM vs PHM or molar vs nonmolar 
pregnancies. This was in agreement with the finding that stromal karyorrhexis couldn’t differentiate 
between POC cases [17]. This was in disagreement with the results of a study including 113 
specimens of POC before 13th week gestation and found that the rate of stromal karyorrhexis was 
significantly higher in early CHM than in PHM (p<0.001). They proved and confirmed that the 
frequent karyorrhexis in the villous stroma is a useful histopathologic parameter in the differential 
diagnosis of CHM from PHM and HA in early gestational age. However, the stromal karyorrhexis 
couldn’t be used as a significant feature in cases showing diffuse hydropic change due to an absence 
of cellular components in the stroma [18]. 
The current study showed that atypia (in the form of increased nucleocytoplasmic ratio, 
hyperchromasia, and pleomorphism) in extravillous trophoblast was mainly of marked degree in 
74% of CHM, and of mild degree in 71% of PHM cases. Marked atypia was in favor of CHM 
diagnosis, while mild atypia was in favor of PHM and HA diagnosis. Marked degree of atypia was 
statistically significant in differentiation between CHM and PHM specimens, while mild degree of 
atypia wasn’t significant in differentiation between molar and nonmolar POC. It may be a useful 
histopathologic feature regarding the diagnosis and classification of HM. This was consistent with 
the observation that trophoblast atypia could differentiate between CHM and PHM where diffuse 
marked atypia was found in most CHM and focal mild atypia in most PHM [22]. This was in 
contrast with others who found that atypia in extravillous trophoblast showed no significant value in 
differentiation between CHM and PHM [17,19]. 
In our study, seven cases diagnosed histopathologically as PHM were reclassified as CHM after 
p57Kip2 immunohisto-chemistry (showed no or scattered nuclear staining in villous CT and villous 
stromal cells). Six of these cases exhibited morphological features similar to PHM on 
histopathological examination in the form of two populations of villi; small and large distended villi 
with irregular outline and multifocal villous trophoblast hyperplasia. One case showed two villous 
populations, circumferential villous trophoblast hyperplasia and trophoblastic inclusion in the core 
of their villi without stromal karyorrhexis. In these cases, we can consider p57Kip2 as a gold 
standard for the diagnosis and classification of HM cases. This was similar to previous observations 
[10]. 
In a retrospective study done by Landolsi et al [2] on 220 specimens of HA, negative p57Kip2 
expression was observed in 8 cases with a histopathological diagnosis of PHM, and in one case with 
a diagnosis of HA. Landolsi et al.[2] tried to explain this negative p57Kip2 expression either due to 
mis-diagnosis of CHM or lack of staining due to loss of antigenicity. They proved the mis-diagnosis 
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of CHM by genotyping analysis of their discordant nine cases and found absence of their maternal 
allele [2]. Funkunaga et al [7] reported artifactual loss of staining due to loss of antigenicity in four 
HA and one PHM cases, but the presence of positive internal control in decidual and implantation 
site trophoblasts in our study excludes this explanation [12]. 
In the current study, one case histopathologically diagnosed as CHM was inconsistent with the 
pattern of p57Kip2 immunostaining which showed positive nuclear staining in villous CT and 
villous stromal cells. This was also found in the results of previous studies in which one case out of 
132 CHM cases was found to show positive p57Kip2 immunostaining in their CT and villous 
stromal cells [2]. This was explained by false-positive immunohistochemistry or a misdiagnosis of 
PHM or HA. Another possibility is the presence of twin gestation, one of them normal and the other 
CHM. Furthermore, rare CHMs are biparental in origin and contain both maternal and paternal 
chromosomal components. They explained it as a mis-diagnosis, as no adequate DNA material was 
available for genetic study to confirm. In such rare cases, we can’t consider p57Kip2 as a gold 
standard for the diagnosis and the matter will require further studies including molecular techniques 
using the differences in DNA content. 
Concerning the follow-up data, nine cases out of the 65 total cases (14%) developed PGTD. They 
were diagnosed based on persistence of their symptoms and their serum β-HCG level which didn’t 
come down to the basal level. Eight cases of these were diagnosed as CHM (18% of total CHM). 
Similar results were found in a study performed by Van Cromvoirt et al [23] to identify cases the 
developed PGTD after CHM; 89 cases (20%) of their total 448 CHM cases developed PGTD and 
required chemotherapy [24-26]. 
According to our results, one case of PHM (9% of total PHM) had developed PGTD. But this was 
inconsistent with the percentage detected in a study done by Wielsma et al [24] which detected 
cases of PHM that developed PGTD; only 6 out of 344 PHM cases (2%) were found to have 
developed PGTD and were treated successfully by methotrexate chemotherapy. Also, it was 
inconsistent with the percentage reported by Chen et al [3] who found that 2.5%–7.5% of PHM can 
progress to PGTD. We can attribute this difference between the two studies to the very limited 
number of the PHM cases studied in the current study. We reviewed these cases histopathologically 
and didn’t find any specific morphological or immunohistochemical features associated with their 
progression to PGTD. In that regard, the current study was in agreement with the histopathological 
and immunohistochemical study done by Petts et al [25] on 150 cases of molar pregnancy. To 
achieve this distinction, further studies are required using a larger number of cases and 
implementing further immunohistochemical markers that may have a benefit. 
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In conclusion, histopathological diagnosis of molar pregnancy remains problematic especially in 
early gestational age. The diagnosis requires a constellation of specific histopathological criteria in 
order not to miss the diagnosis of CHM. p57Kip2 immuno-histochemistry is of great value in the 
diagnosis of cases that have equivocal morphology by histopathological examination. However, 
there are no significant features to predict cases that subsequently develop persistent trophoblastic 
disease. Further immunohistochemical markers should be studied to accurately distinguish PHM 
from CHM and also to predict patients’ outcome. 
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Abstract. 
Recurrent hydatidiform moles are defined by the occurrence of two or more molar pregnancies in the same 
patient. A familial recurrent hydatidiform mole (FRHM) is a rare autosomal recessive condition where 
women have an inherited predisposition to have molar pregnancies. Genotyping demonstrated that they are 
diploid and biparental.                   
We report a case of FRHM from Egypt with a history of 6 recurrent complete moles. Sequencing of the 
NLPR7 gene revealed a deleterious homozygous base change in exon 2, c.197G>A, which would result in a 
truncated protein p.W66*. To the best of our knowledge, this mutation has not been described before. 
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Introduction 
Hydatidiform mole is the most common type of gestational trophoblastic disease and may be 
complete (CHM) or partial. It is a human pregnancy characterized by excessive trophoblastic 
proliferation and abnormal embryonic development that may be sporadic or recurrent [1]. Recurrent 
hydatidiform moles (RHMs) are defined by the occurrence of two or more molar pregnancies in the 
same patient. The frequency of RHMs in England has been reported by Sebire and colleagues to be 
1-2 % [2]. However, higher frequencies of RHMs have been reported from the Middle and Far East; 
where it ranges from 2.5 to 9.4% [3]. Familial recurrent hydatidiform moles (FRHM) is a rare 
autosomal recessive condition where CHM are diploid and biparental (BiCHM) in contrast to 
sporadic CHM which are androgenetic (AnCHM) [4] . Eagles and colleagues reported that in the 
UK 1 in 640 women registered with a CM (0.16%) has this rare condition [4].                                                                                                                
Maternal-effect genes are needed in the oocytes to sustain normal embryonic development until the 
activation of the embryonic genome. Most patients with FRHM, with mutations in both alleles of 
NLRP7, produce no normal functioning protein necessary to achieve a normal pregnancy [5]. Kou 
and colleagues have previously identified an intragenic duplication of exon 2-5 in NLRP7, which is 
likely to be the cause of biparental FRHM in 3 unrelated Egyptian families with FRHM [6]. There 
were no reported mutations in NLRP7 or KHDC3L in women with AnCHM [7]. Akoury and 
colleagues reported that women with recessive NLRP7 mutations fail to have normal pregnancies 
from spontaneous conceptions except for 5 out of 131 reported patients resulted in 6 live births 
[8].                                                      
Because there is no current treatment for RHM, ovum donation appears the best management option 
for these patients to achieve normal pregnancies [7]. However, ovum donation is not accepted in 
some communities and is prohibited in Islamic countries.                                                                                                                           
 
Methods. 
We describe a case of a female with recurrent six CHM who has been managed at Mansoura 
University Hospital, Egypt.  
The available hematoxylin-stained slides of her molar pregnancies were reviewed for confirmation 
of RHM after being sent to Trophoblastic Disease Screening and Treatment Centre, Imperial 
College London, Charing Cross Campus, United Kingdom. Genotyping was performed, using 
paraffin-preserved tissue blocks from the 5th CHM. After confirmation that this was a BiCHM; 
sequencing of the coding exons of NLRP7 was performed on genomic DNA of the patient as 
previously described [9].                                                                                                  
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Case  
A 26 years old otherwise healthy female, G6P0A6, and her 31 years old healthy husband were 
evaluated after 6 CHM. There was a history of consanguinity between the patients' parents but not 
between the patient and her husband. There was no history of molar pregnancies among the families 
of the patient or her husband.                              
 Her first pregnancy was misdiagnosed as missed abortion and was surgically evacuated. The 
patient complained of heavy vaginal bleeding after 20 days of uterine evacuation, ultrasound 
revealed a residual mass in the uterine cavity measuring 3 x 2 cm, and serum beta human chorionic 
gonadotropin (β-hCG) was 300,000 mIU/mL. She went through a second curettage, after which the 
β-hCG sharply declined and normalized. Histopathology of this evacuation product was consistent 
with CHM.        
She conceived five more times; all pregnancies were documented to be CHM by ultrasound and 
histopathological examination of uterine contents. Spontaneous regression of β-hCG titer after 
evacuation occurred within 6-8 weeks. The patient received oral contraceptive pills for one year 
after each pregnancy. The patient did not develop persistent trophoblastic disease after evacuation 
of any of the six molar pregnancies.  
After consenting of the couple; the available hematoxylin-stained slides of the pregnancies were 
reviewed, all were consistent with CHM. Genotyping of the paraffin – preserved tissue from the 
fifth pregnancy showed it to be diploid and consistent with a biparental origin. This is consistent 
with a diagnosis of FRHM. Subsequently genetics testing for mutations in the NLPR7 gene was 
performed on genomic DNA from the patient.  Sequencing of NLRP7 revealed a deleterious 
homozygous base change in exon 2, c.197G>A, which would result in a truncated protein p.W66* 
(figure 1).                                                                                                                                                                
 
Discussion. 
FRHM is a rare condition, in which the affected women have a predisposition to CHM. FRHM can 
be diagnosed by demonstrating the molar pregnancies are BiCHM in contrast to sporadic CHM 
which are androgenetic [9]. Approximately 70% of women affected by FRHM are associated with 
recessive mutations of NLRP7 [10].                                                                                                   
We report a case of FRHM with history of consanguinity but no family history of a similar 
condition although other authors reported the familial incidence [11,12]. Mutations in NLRP7 have 
been reported in patients with RHM. Till now, 249 sequence variants are listed; 89 are reported to 
be pathogenic [13]. These mutations include stop codons, small deletions or insertions, splice 
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mutations, large deletions or insertions, complex rearrangements, and protein-truncating mutations 
[14]. Furthermore, Ulker et al. reported a deletion of 60-kb extending from intron 8 of NLRP7 to 
intron 11 of NLRP2 [15]. In the present case a novel deleterious homozygous base change in exon 
2, c.197G>A would result in production of a truncated protein p.W66*.This mutation is different 
from what previously identified by Kou and colleagues Kou and colleagues [6] in 3 unrelated 
Egyptian families with FRHM.                                                                                                                             
It was suggested that defective oocytes are responsible for the pathophysiology of RHM. This 
finding was confirmed when assisted reproductive cycles using donated oocytes in three patients 
with recessive NLRP7 mutations resulted in four normal offspring [8]. Unfortunately, at present 
ovum donation, which is not acceptable in some communities, is probably the most likely way of 
achieving a normal pregnancy, although a small number of normal pregnancies have been reported 
in women with FRHM [8]. In addition, Fallahian and colleagues reported a case of two sisters with 
diploid biparental complete moles. They have a total of six molar pregnancies with no living child. 
One of them finally conceived of apparently normal female fetus but the placenta showed diffuse 
molar changes [11]. Spontaneous conceptions in patients with recessive NLRP7 mutations are rare 
and usually associated with missense mutations8, rather than the protein truncating type of mutation 
in our patient.                                                                                                                                                
The patient did not develop gestational trophoblastic neoplasia (GTN) consistent with other 
reported studies that the incidence of GTN is not higher in women with FRHM than those with 
typical sporadic CHM [4,12]. However, further researches may be needed to clarify this point.                                                                                               
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Figure 1: Partial sequence, c.183-198, of NLRP7 showing a homozygous base change 
c.197G>A in a patient with FRHM. 
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  The mutation results in a change in the amino acid sequence which introduces a stop codon and a 
truncated protein, p.W66*  
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10.1 General discussion 
In this thesis, we describe our investigation on the epidemiology, clinicopathologic features, and 
outcome of treatment of GTD at Mansoura University Hospital (chapters 2, 6-8); treatment 
modalities of women with GTN at 40 years or above (chapter 3); and the role of second curettage in 
treating low-risk GTN (chapter 4). Subsequently, we discuss the secondary benefits of collaboration 
between the GTD clinic of Mansoura University, Egypt, and the Erasmus MC Cancer institute, 
Erasmus University, Rotterdam (chapter 5). 
 
Epidemiology, pathologic features, and outcome of GTD at Mansoura University, Egypt 
The incidence of GTD varies globally according to geographic locations. Moreover, the incidence 
in many non-western countries, including Egypt, is underestimated because of lack of proper 
diagnostics and proper registration. 
We assumed that the incidence of GTD in our locality is underestimated due to reluctance in 
performing routine histopathologic examination of products of conception. It is often difficult to 
differentiate retained products of conception from GTD solely on the basis of clinical criteria or 
imaging; only 40%–60% of CMs and PMs are detected by ultrasound. Contrastingly, 10% of 
suspected CMs and PMs are non-molar hydropic abortions on histological examination. 
To explore the prevalence of GTD in the specimens of pregnancy termination and post-abortive 
bleeding, we reviewed 640 specimens of the contents of uterine evacuation referred from 2009 to 
2014 to the pathology department of Mansoura University. The histopathological diagnoses were 
correlated to pre-evacuation clinical and ultrasound data, as supplied to the pathologists through 
referred clinical reports. We found that partial and complete molar pregnancies were histologically 
diagnosed in 20.6% of the referred cases of miscarriage, which was surprisingly higher than the 
reported value of nearly 3%. This may be explained by the small sample size of our study. Other 
explanation is overestimation of molar pregnancy in our study because we included cases referred 
for histopathological assessment. The third reason is real different incidence of GTD due to 
differences in geographic distribution. 
Undoubtedly, many cases of pregnancy termination in our locality are not subjected to 
histopathological examination. The most important argument reported was that the clinician was 
satisfied with his or her clinical and ultrasound diagnosis and felt confirmation superfluous. Another 
reported reason was the non-availability of pathology laboratories near the clinics in rural areas. 
Ch. 10 │ General Discussion and future perspectives  
 
106 
Unfortunately, this is a common problem in the non-Western countries. In case expectant 
management of miscarriage is followed, the products of conception are often expelled at home; this 
decreases the chance of specimen examination. In case of persistent or recurrent bleeding, a 
subsequent curettage follows, and pathological examination is of greater importance in such groups 
because it can indicate GTN. The authors recommended routine histopathological examination of 
the products of conception and post-abortive bleeding. If the pathological examination service is not 
available, the gynecologist should at least inspect the product of miscarriage for the presence of any 
vesicles and ask the patient for weekly check-up of hCG levels till normalization. To resolve this 
problem, government should establish pathology laboratories at least in district hospitals. Training 
courses and national meetings for gynecologists and obstetricians can be good events to announce 
the importance of routine histopathological examination of the products of conception. Training 
courses regarding the methods of diagnosis and treatment of GTD are annually organized by the 
GTD clinic of Mansoura University. 
We aimed to explore the incidence and outcome of GTD in Lower Egypt by conducting an 
observational prospective study. Patients were recruited for 12 months from September 2015 to 
August 2016 following the establishment of the GTD clinic at Mansoura University and the 
constitution of a local GTD registry. The GTD clinic at Mansoura University is the first sub-
specialized clinic in Egypt. The characteristics, management, and outcome of the patients are 
reported in chapter 2. The hospital-based incidences of molar pregnancy and GTN in Mansoura 
University Hospital were estimated to be 13.1 and 3.2/1000 live births, respectively. This hospital-
based incidence is more than that reported in Taiwan (8.0/1000 deliveries) and Indonesia (9.9/1000 
pregnancies). These figures are not the exact figures of incidence of GTD in Delta region, Egypt, 
because some cases were managed in private clinics. We hope to produce accurate figures in near 
future when our clinic becomes the only center managing GTD. The reason for relatively high 
incidence of molar pregnancy in our locality is that Mansoura is a referral center of the entire Lower 
Egypt. Other reasons are related to socioeconomic factors, such as early age of marriage, pregnancy 
at maternal age of 40+ years, and less intake of folic acid in diet. Progression to GTN, during 
follow-up, was found to be 16.1%, which is more than that reported by other authors. The variation 
in molar progression to GTN in different studies reflects selection bias, but it also reflects different 
outcomes among different countries. High rate of GTN progression in low-resource countries 
should be discussed by health care providers in these countries. Moreover, the methods of 
diagnosis, treatment, and follow-up of molar pregnancies should be improved. Furthermore, some 
authors have recommended a single-dose prophylactic chemotherapy to patients with criteria of 
high-risky moles during evacuation to reduce molar progression to GTN. 
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The ratio of CM to PM in our study was 1.3, which is higher as compared with other reports. This 
may be explained by the small sample size in our study. However, the high ratio also denotes a 
more frequent diagnosis of PMs (misdiagnosis) or true higher incidence of PM pregnancies. In 
many cases, histopathological differentiation between CMs and PMs is difficult, which may 
necessitate the use of immunohistochemistry showing p57Kip2 or additional genetic studies of the 
gestational product. It is well-known that p57Kip2 identifies CM by lack of its expression. In 
chapter 8, we aimed to investigate the expression of p57Kip2 in molar pregnancies and their 
relation to the progression to persistent trophoblastic disease. A total of 65 specimens of the 
products of conception were reviewed clinically and pathologically, and any progression to 
persistent GTD was reported. After immunohistochemical staining of p57Kip2, diagnoses of seven 
cases (10.8%) changed from PM to CM. This is in line with the findings of other authors. Proper 
differentiation between CM and PM is critical as the rate of progression to GTN is higher in CM 
than in PM (20% versus 5%), necessitating more attention during follow-up. Furthermore, we found 
no significant differences in any morphological or immunohistochemical characteristics between 
cases with or without subsequent development of GTN. 
Conclusively, p57Kip2 immunohistochemistry is of great value in the diagnosis of molar cases and 
implemented in the pathology service in most Western countries. However, being an expensive tool, 
p57Kip2 immunohistochemistry and genotyping are not routinely available in non-Western 
countries with limited resources. To solve this problem, both should be performed in a unique 
central laboratory. Government or non-governmental organizations can be invited to support this 
sub-specialized laboratory. This central laboratory should perform pathology review for a large 
area, and it needs to be validated externally according to international standards. Correct diagnoses 
will improve care for individual patient and guide clinicians to give the best post-surgery follow-up 
advice. 
When such tests are not available and concerns regarding the histopathological diagnosis remains, 
clinicians may want to advice patients regarding hCG monitoring similar to the protocol for 
complete molar pregnancy to prevent late diagnosis and treatment of persistent GTD. 
During the decision-making for gynecologic cancer, tumor board often faces a challenge between 
oncological and reproductive outcomes. Most GTN cases occur in young women; thus, fertility-
preserving and future procreation are often discussed with patients and their families, particularly in 
non-Western countries. Reproductive outcomes of fertility-preserving treatment for premalignant 
and malignant gynecologic diseases are presented in chapter 6. Our study included 43 GTN cases. 
We reported that pregnancy following chemotherapy (43 and 5 cases of GTN and stage 1c ovarian 
cancer, respectively) resulted in 3 of 48 (6.3%) missed abortions and 1 case of induced abortion. 
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Adverse pregnancy outcomes were not correlated to the number of chemotherapy cycles but 
correlated to shorter interval between the previous chemotherapy and subsequent pregnancy. We 
found that reproductive outcomes after fertility-preserving treatment of GTN were comparable with 
those of general population, which agreed with other published studies. However, we reported 
increased rates of cesarean delivery, intra-abdominal adhesions, missed abortion, and congenital 
fetal malformations. Moreover, one case developed relapse of GTN 1 month after delivery, which 
necessitated continuing postpartum surveillance of the cured patients. 
To conclude, reproductive outcomes after fertility-preserving treatment of GTN were similar to 
those of the general population. With the ongoing prospective data collection of the GTD clinic at 
Mansoura University, we aim to further clarify this in future. The long-term effect of chemotherapy 
on obstetric outcome is still unclear and needs to be evaluated in a large prospective study. In some 
cases, pregnancy occurred within a short period after chemotherapy, either intended by the patients 
or after forgetting oral contraceptive pills; thus, this information should be provided while advising 
regarding pregnancy continuation in women who conceived shortly after cessation of 
chemotherapy. 
RHM is defined as the occurrence of two or more moles. Familial RHM (FRHM) is a rare 
autosomal recessive condition. Chapter 9 presents a novel genetic mutation in an Egyptian patient 
with recurrent biparental CHM. Sequencing of NLPR7 revealed a deleterious homozygous base 
change in exon 2, c.197G>A, resulting in truncated protein p.W66*. This test was performed in the 
laboratory of Trophoblastic Disease Screening and Treatment Centre, Imperial College, London, 
Charing Cross Campus, United Kingdom; this facility is not available in Egypt. Recently, an 
international collaboration was initiated between the GTD Clinic of Mansoura University, Egypt, 
and McGill University, Canada, due to which these tests are now available for women at the GTD 
Clinic of Mansoura University; this has resulted in diagnosing gene mutations in more Egyptian 
women. Results of such genetic studies were published within a large number of patients from 
different countries. 
Maternal-effect genes are needed in the oocytes to sustain normal embryonic development until the 
activation of embryonic genome. Most patients with FRHM, with mutations in both alleles of 
NLRP7, do not produce normally functioning proteins necessary to achieve normal pregnancy. 
Thus, ovum donation is the best management option for these patients to achieve normal pregnancy. 
However, ovum donation is prohibited in Islamic and many Eastern countries. This leaves no 
treatment for RHM. Providing honest and unbiased information to the couple and other involved 
family members is crucial. The knowledge of carrying such a mutation is distressing for a couple 
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and other affected females in a family. It may lead to family breakdown when healthy offspring is 
not guaranteed. 
Since some authors have reported sporadic occurrence of normal pregnancy in cases of RHM, the 
disease should be clearly described to a couple by a specialized gynecologic oncologist with focus 
on the importance of genetic analysis and very low chance of normal pregnancy. Follow-up should 
be ensured not only for molar pregnancies but also for subsequent pregnancy outcomes. At the GTD 
clinic at Mansoura University, we diagnosed over 30 females with recurrent mole during September 
2015 to August 2019; to our knowledge, this is one of the largest number reported. Some of these 
women had a family history of RHM or recurrent miscarriages without pathological diagnosis. Still, 
some of the patients with RHMs finally had a healthy baby, whereas most did not. We plan to 
analyze the outcome of these patients to analyze whether we can predict if and when favorable 
pregnancy outcome can be expected. 
Familiar RHM is recessive; thus, in countries with high rates of consanguine marriages, this will be 
expected to be a noticeable problem. Consanguinity is more prominent in low-resource countries, 
particularly in traditional countries, than in high-resource countries. Thus, we would like to plea for 
an internationally funded central laboratory that makes such tests assessable for each couple facing 
such problems regardless their religion or country. Preferably, the test should be performed using 
saliva instead of blood because it is easier to send scrapings across oceans than tubes. 
 
Treatment outcome in women with GTN at 40 years old and above 
To answer this question, we investigated the outcomes of different treatment strategies for GTN in 
women aged 40 years and over in a multicenter retrospective study. Treatment of GTN at old age 
(40 and more years) is poorly studied even though the incidence of molar pregnancy increases in 
pregnant women at that age. Subsequently, women aged 40 years and over are considered at high 
risk of developing post-molar GTN. There are no established guidelines for different treatment 
strategies for GTN at 40 years or over. In chapter 3, we presented the experience of five different 
centers in five countries in four continents (Africa, Asia, Europe, and North America) in the 
management and outcome of GTN in women at 40 years or more. This study had several 
limitations, such as its retrospective design, heterogeneity of data reporting from different centers, 
different local hospital protocols for the management. Moreover, we could not obtain central 
pathology review of histopathology of the cases. The strength of our study is the considerable size 
of the cohort with finally 110 patients available for analyses. 
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In short, we observed that hysterectomy is performed in many cases in the setting of first-line 
treatment. This is logical considering that in this study; patients completed their families and were 
aware of their reduced fertility. In low-risk non-metastatic GTN, complete remission was reached in 
97.1% of the cases. This high cure rate may be attributed to the adjuvant use of 1–2 courses of 
MTX after hysterectomy in most participating centers. 
Surprisingly, 43% and 56% of women with low-risk and high-risk metastatic disease were initially 
treated with hysterectomy along with chemotherapy, denoting more frequent use of hysterectomy in 
the participating centers in this age group. For the high-risk group, complete remission was 
achieved in 60% of cases who received hysterectomy in combination with chemotherapy compared 
with 50% of patients who received only chemotherapy. Thus, adjuvant hysterectomy may benefit 
cautiously selected patients with high-risk GTN, but it should not delay systemic treatment because 
this remains as the cornerstone of treatment. 
Compared with international literature, women with GTN at 40 years old or over were more often 
categorized to have high risk, higher rates of failure of the MTX/FA regimen in the low-risk group, 
and higher mortality than GTN in younger patients, all denoting a poorer prognosis of GTN at 
higher age. This may be attributed to different biological behavior of the tumor. The concept of 
abnormal biological behavior of GTD at older age is supported by the reported increased incidence 
of molar progression to GTN (up to 56% in women above 50 years of age). There is also an 
increased tendency to chemotherapy resistance as reflected in FIGO risk scoring system where 40 
or more years of age is scored with a point more than younger age group. 
We observed that a relatively large number of patients did not receive the treatment according to 
international standards. In lower-resource settings, the adverse effects of multi-agent chemotherapy 
on critically ill patients are feared for; thus, adjusted schedules are needed. In daily practice, step-up 
schedules are used, such as mono MTX, but they should be followed, e.g., by EMA/CO shortly 
after the first response because it induces drug resistance and treatment failure and lengthens 
treatment time unnecessarily. International consensus of experienced clinicians should prepare such 
protocols. Prospective gathering of clinical data and outcome globally should enable communities 
to improve knowledge and establish future protocols. Since large international studies are difficult 
to perform and costly, an easier way is needed to proceed with such projects. 
To conclude, for treatment of low-risk non-metastatic disease at old age, hysterectomy with 1–2 
courses of single-agent chemotherapy is quite successful and should be discussed with patients as 
an alternative to hysterectomy or single-agent chemotherapy (MTX/FA or Act-D). A large 
prospective randomized study can deliver the data to support this. Such randomized study will 
random low-risk non-metastatic GTN in women at 40 or more years of age into 2 or 3 groups; the 
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intervention groups will undergo hysterectomy with or without adjuvant single course of MTX, and 
the control group will receive single-agent chemotherapy with MTX till remission. The primary 
endpoint will be remission rate (normalization of serum hCG level), whereas secondary endpoints 
will be the duration of treatment and complications. The GTD clinic at Mansoura University would 
like to conduct this randomized study in collaboration with other international centers. 
 
Role of second curettage in treatment of low-risk non-metastatic GTN 
The impact of second curettage on number of chemotherapy courses, duration of treatment, relapse, 
and complications during treatment of post-molar GTN is presented in chapter 4. 
We assumed that second curettage in post-molar GTN produces a “debulking effect” and 
subsequently reduces the number of chemotherapy courses needed to achieve remission. To study 
this, we conducted the first randomized controlled study to compare second curettage plus 
chemotherapy versus chemotherapy alone in patients with post-molar GTN. The study was 
conducted at Mansoura University Hospital, Egypt, and followed the international guidelines of 
research conduct. The patients were randomized 1:1 by means of a web-based system, using 
random block sizes. An intention to treat analyses was performed, including 43 cases in each 
treatment arm. 
We found no significant difference between the two groups. Our results are in line with one 
retrospective study that concluded that dilatation and curettage of GTN do not affect future 
chemotherapy requirements; however, the results are also in contrast with two other retrospective 
and one prospective study. The curative effect of second curettage was not awaited in our study as 
all patients initially received MTX. Failure of MTX and need of second-line therapy were observed 
in 15% of the patients; this is in line with previous reports. Since this result was unexpected, we 
performed an unplanned substandard care analysis to see if results could be compromised by 
differences between two treatment arms. We did not find any factors that might have influenced 
these findings. Therefore, we concluded that a second curettage should not be performed in low-risk 
GTN unless treatment effect (normalization) is awaited for. 
In depth, analyzes showed that several factors are at stake that may be of importance in the 
treatment in other non-Western countries too. We found that treatment cycles with a duration of 
17.9 days (comparable in both groups) were longer than the expected 14 days. This was contributed 
to patient-related factors, such as reluctance to perform blood tests on time and switch to a second-
line treatment, difficulties in reaching a clinic, and financial burdens, whereas others were external 
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factors, such as poor availability of MTX or other second-line drugs in Egypt in certain times due to 
logistic factors. Therefore, while performing such studies, it should be considered that 
circumstances for participants should be optimized regardless the allocated treatment arm. To 
encourage the recruited cases to receive the allocated treatment, the medication (MTX and folinic 
acid vials) were offered free of charge by the GTD clinic, Mansoura University Hospital. To ensure 
attendance of follow-up, the patient was contacted over a phone in case of delayed visit. 
MTX is available in vials of 50 mg, and in this study, MTX was administered in a fixed dose (50 or 
75 mg), allowing subsequent courses to be administered by a nurse in a home setting. The 
(international) discussion on the best MTX dosing regimen is not yet settled, and some favor a dose 
related to body weight (1 mg/kg) rather than a fixed dose. Since the two treatment groups were 
comparable regarding body weight and BMI, the regimen and dosing in this study are unlikely to 
have affected the primary outcome. However, it is interesting to address this issue in an 
international study too. We could not trace down the reason for an international community to 
choose for a fixed dose of 50 mg. In our study, the women had an average weight of 73.5 kg; thus, 
many might have had a dose >1 mg/kg. It may be necessary to reconsider the strength of fixed dose. 
In the current era of high numbers of overweight women, it may be needed to adjust the standard 
dose according to weight, i.e., it can be 50 and 75 mg in women weighing <65 kg and >66 kg, 
respectively. The industry should be advised to provide ampoules of these two strengths. 
Similar problems can be at stake, such as regular hCG level monitoring after molar or post-molar 
GTN with normalization of hCG level as per protocol. To overcome these problems, the woman 
was asked to perform and report on urine pregnancy tests. Initially, the tests were performed weekly 
and then monthly. When the urine test turns positive, the patient was asked to go to a hospital for a 
serum test and ultrasound scan. Each patient may be granted 6–10 urine testing kits and should be 
instructed on how to use it. She was asked to bring in the completed tests during each follow-up 
visit. 
Chapter 5 presents the letter to the editor titled “collaboration benefits all”. This reflects the 
experience of authors from Netherlands and Egypt while conducting the aforementioned 
randomized study. The collaboration between Western and non-Western countries is essential 
because it helps in finding proper treatment in many diseases, which are prevalent in low-resource 
countries. Western countries implement science, knowledge, and advanced technology during 
proper scientific researches. However, some diseases are rare in Western countries; thus, many 
years are needed to conduct a study with a proper sample size. Conducting a well-designed RCT 
according to the international guidelines may be difficult in low-resource settings with high 
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incidence of these diseases due to poor infrastructure and limited resources. Lack of patients’ and 
physicians’ awareness regarding importance of conducting researches is yet another obstacle. WHO 
encourages this cooperation and helps implement these researches in prevalent diseases in Africa, 
such as AIDS and cervical cancer. The research collaboration should follow ethics of medical 
researches, especially ensuring safety, community acceptability, and expected health benefits of 
enrolled patients. 
Other spin offs of this collaboration include the launch of the first GT clinic in Egypt, which now 
serves as a referral center for patients in Lower Egypt, and the development of a leaflet for patient 
information in Arabic explaining molar pregnancy of a patient information . We summarized that 
this collaboration, which was experienced during the conduct of our RCT, helped improve patient 
management and quality of research at Mansoura University Hospital, Egypt. The authors 
recommend collaboration in scientific researches between Western and non-Western countries. 
As a spin-off of this collaboration and research, the author of this thesis was nominated as the 
representative of North Africa in the International Society of Study of Trophoblastic Disease 
(ISSTD). 
 
10.2 Future perspectives 
Improvement of the management of GTD at Mansoura University Hospitals, Egypt, necessitates 
more efforts. The author of this thesis initiated a specialized GTD clinic in 2015, which was the first 
in Egypt and became the principle referral center in Lower Egypt. A strict registry of all cases of 
GTD has been established for analyzing accurate data of incidence, prevalence, and outcome. The 
initiation of Egyptian national registry of GTD is yet another challenge. The registry can be 
organized by designing a website to include the database of GTD cases from different parts of 
Egypt. Any interested and dedicated colleague from each university hospital can log in the website 
with a special password. The basic data to be registered for each case include name (*), date of birth 
(*), residence, weight, parity, medical history, family history, presentation, hCG level (*), 
ultrasound criteria, final diagnosis (*), treatment (*), and follow-up details (*); * indicates 
obligatory fields. After establishing this website, national statistics of incidence and outcome will 
be easily estimated. Furthermore, this website should have an open access that provides patients and 
care givers with proper and checked information regarding treatment and prognosis. Since many 
women in Egypt are illiterate, the information should also be available in local language. Women 
from the society who suffered from different GTN diagnoses could be asked to participate in this 
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informative website. A closed part could be used for patients and family members to ask questions 
regarding difficult issues, such as hereditary forms and resuming procreation and intimacy. 
A specialized workshop is organized annually at Mansoura University in collaboration with the 
ISSTD to increase the knowledge and skills of general gynecologists in the management of GTD. 
In future, GTD workshops will also be organized with the help of ISSTD in other countries of North 
Africa. The gynecologists from these countries will be helped to initiate specialized GTD clinics 
and start GTD registries, improving local knowledge on GTD and treatment outcomes of such 
patients. 
International collaboration in GTD research is another important perspective. GTD is common in 
South-East Asia and Middle-East, whereas it is rare in the Western countries. Many countries with 
high incidence of GTD have limited resources and poor infrastructure for scientific researches; thus, 
an international collaboration between Western and non-Western countries in conducting GTD 
research, which follows the international standards and ethical guidelines, will aim at solving health 
problems that are more prevalent in low-resource countries than—but still present in—Western 
countries. 
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11.1 English summary. 
The aim of this thesis was to address studies on gestational trophoblastic disease with emphasis 
on improving care in Egypt, and second curettage in treatment of low risk gestational 
trophoblastic neoplasia (GTN) which was not studied before in a randomized study. 
In chapter 1, a brief introduction about epidemiology, classification, diagnosis, treatment, and 
future fertility of gestational trophoblastic disease. In the last section; objectives of the study 
were presented. 
In chapter 2, incidence, demographic criteria, and prognosis of GTD in Mansoura University 
Hospital were addressed. Incidence and outcome of GTD cases were addressed in an 
observational prospective study conducted at the GTD Clinic of Mansoura University which serves 
most of Lower Egypt. The patients were recruited for 12 months from September 2015 to August 
2016. We reported 71 clinically diagnosed GTD cases, 62 of them were histologically confirmed, 
58 molar (33 CM and 25 PM) in addition to 4 initially presented GTN cases. The incidence of 
molar pregnancy and GTN at Mansoura University Hospital was estimated to be 13.1 and 3.2 per 
1000 live births respectively. The population-based incidence of molar pregnancy and GTN were 
0.37 and 0.09 per 1000 live birth respectively. Mean age of the studied cases was 26.22 years. Mean 
pre-evacuation hCG was 136,170 IU/l. Most of the cases diagnosed accidentally after abnormal 
sonographic findings (53.2%). The rate of progression of CM and PM to GTN was 24.2% and 8%, 
respectively and no significant difference between CM and PM regarding hCG level, time to hCG 
normalization, and progression rate to GTN. 
In chapter 3, a retrospective, multicenter study that aimed to investigate the outcome of different 
treatment strategies in patients with gestational trophoblastic neoplasia (GTN) at 40 years old or 
above. We analyzed data from 5 referral centers from 5 countries (Egypt, Canada, Ukraine, Saudi 
Arabia, and Indonesia) during last 5 years. Medical records of 118 women with GTN were 
retrieved, reviewed and analyzed. Demographic criteria and outcome of different treatment 
strategies were evaluated.  
A total of 118 cases were identified. Mean age was 45.4 years. Of 80 patients with LR non 
metastatic GTN, 46 women were treated with monochemotherapy. In 34 a hysterectomy with or 
without (n = 4) chemotherapy was performed. Upfront hysterectomy with or without methotrexate 
was associated with higher remission rate and shorter treatment duration (P=0.001). In 14 patients 
with low-risk metastatic GTN, remission rate was 50% for both MTX alone and MTX plus 
hysterectomy. Two of the 18 high risk patients died before treatment could start and one patient 
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died during treatment due to distant metastases. Ten HR cases underwent hysterectomy and 
chemotherapy as first line; 60% achieved remission. Four women were treated with EMA/CO 
alone; two of them (50%) had incomplete response and needed 2nd line EMA/EP combination.           
We concluded that the highest remission rate was seen in the low-risk non-metastatic disease group 
treated with hysterectomy and subsequent 1-2 courses of methotrexate and hysterectomy with 
combination chemotherapy in high-risk disease. A large prospective randomized study is 
recommended to verify these findings. 
Chapter 4, presents a randomized-controlled study comparing second curettage plus 
chemotherapy versus chemotherapy alone. We analyzed 43 patients in each group. The two 
groups were comparable regarding the basic characteristics. The study concluded that there 
were no significant difference between the two groups regarding number of chemotherapy 
courses, methotrexate failure, complications of chemotherapy, and rate of relapse. Moreover, 
only serum hCG was related to number of chemotherapy courses.  
In chapter 5, a letter to the editor which addressed the importance of collaboration in scientific 
research between developed and developing countries giving the presented RCT in this chapter 
as an example. The letter clarified that some diseases as GTN and cervical cancer are more 
common in the developing countries which may have poor resources and infrastructure to 
conduct proper studies according to the international studies. Other benefits of this collaboration 
included the launch of the first trophoblastic clinic in Egypt, which now serves as a referral 
centre for patients in the surrounding area, and the development of a patient information leaflet 
in Arabic on molar pregnancy.  
In chapter 6, we evaluated the obstetric outcome of patients who had undergone fertility preserving 
treatment for gynecologic premalignant and malignant diseases including gestational trophoblastic 
neoplasia. The study reviewed the pregnancy course and delivery data of 60 patients (including 43 
GTN cases), who conceived after fertility sparing treatment from January 2012 to December 2015. 
We reported pregnancy complications, abnormalities during labor, neonatal outcome and any 
recurrence after delivery. We found the mean age of the studied patients was 24.9 years. The 
preceding lesions included gestational trophoblastic neoplasia (GTN), 43 cases (71.7%) while early 
ovarian carcinoma (14 cases, 23.3 %) and least CIN III (2 cases, 3.3%) and micro-invasive cervical 
carcinoma (one case, 1.7%). All cases of GTN were treated with single or multiple agents’ 
chemotherapy. The 3 cases of cervical micro-invasive carcinoma and CIN III were treated with loop 
electrosurgical excision procedures (LEEP). Cases with stage 1a ovarian cancer were treated with 
unilateral salpingo-oophorectomy with peritoneal cytology and biopsy of the other ovary. Missed 
abortion was diagnosed in 4 cases (6.7%). The rate of caesarean delivery was high (70.9%). Intra-
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abdominal adhesions were seen in 20.5% of cases.  The neonatal outcome was normal in 53 cases 
while 2 cases (3.6%) of had congenital fetal malformations. The poor neonatal outcome was 
significantly correlated to number of chemotherapy cycles (P=0.04).  
In chapter 7, we studied prevalence of GTD in the referred specimens of uterine evacuation after 
miscarriage and post-abortive bleeding to the department of Pathology, Mansoura University and 
private practice settings during the period from 1/1/2009 to 31/3/2014.  
Six-hundred referred specimens of contents of uterine evacuation. The mean age of the cases was 
26.5 years. The mean gestational age was 10.3 weeks. The commonest clinical diagnosis of the 
referred cases was missed abortion (51.4%). Molar pregnancy was diagnosed histologically in 103 
of 499 referred cases as miscarriage (20.6%). Histopathological examination of specimens of 
uterine curettage due to post-abortive bleeding revealed GTN in 12 of 27 cases (44.4%). We 
recommend routine histopathologic examination of uterine contents after pregnancy termination and 
post-abortive bleeding.  
In chapter 8, expression of p57Kip2 in early molar pregnancies and their relations to the 
progression to GTN was studied. Sixty-five specimens of products of conception were reviewed 
clinically and pathologically, and any progression to GTN, if present, was noted. Pathological 
assessment of the archival material included re-cut sections of 5 μm in thickness, routine staining 
with hematoxylin and eosin and immunohistochemical staining of p57Kip2.Certain 
histopathological criteria were found to be significant in differentiation between complete 
hydatidiform mole and partial hydatidiform mole including villous shape and outline, villous 
trophoblastic hyperplasia, and atypia in extravillous trophoblasts. There were no significant 
differences in any morphological or immunohistochemical features between cases with or without 
subsequent development of GTN. We concluded after this study that p57Kip2 
immunohistochemistry is of great value in diagnosis of cases that had equivocal morphology. 
However, there were no significant features to predict cases that subsequently developed GTN. 
In chapter 9, we reported a case of FRHM from Egypt with a history of 6 recurrent complete 
moles. Sequencing of the NLPR7 gene revealed a deleterious homozygous base change in exon 2, 
c.197G>A, which would result in a truncated protein p.W66*. To the best of our knowledge, this 
mutation has not been described before. 
Chapter 10 discusses the findings of the presented studies, their impact on clinical practice, and 
future perspectives. 
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11.2 Nederlandse samenvatting (Dutch summary). 
Dit proefschrift onderzoekt verschillende aspecten van trofoblast ziekten, met de nadruk op het 
evalueren en verbeteren van de zorg in Egypte, en op het effect van een tweede curettage op het 
aantal chemotherapie kuren in het geval van laag-risico, persisterende trofoblast ziekte (GTN). 
Hoofdstuk 1, bestaat uit een korte introductie over epidemiologie, classificatie, diagnose, 
behandeling, en toekomstige vruchtbaarheid van GTN. In het laatste gedeelte worden de  
doelstellingen van het proefschrift en de onderlinge samenhang van de verschillende studies 
gepresenteerd. 
 
Hoofdstuk 2, beschrijft de incidentie, demografische criteria en prognose van GTD in het 
Mansoura University Clinic. Dit betreft een prospectieve, observationele studie van de patiënten 
behandeld in de gespecialiseerde trofoblastziekte kliniek (GTD kliniek) van Mansoura 
Universiteit. Patiënten uit het gebied Neder-Egypte worden hiernaar toe verwezen. De patiënten 
werden gerekruteerd van september 2015 tot augustus 2016. We rapporteerden 71 klinisch 
gediagnosticeerde GTD-casus, waarvan 62 histologisch bevestigd, 58 mola en 4 andere GTN-
casus. De incidentie van mola zwangerschap en GTN in Mansoura University Clinic werd 
geschat op respectievelijk 13,1 en 3,2 per 1.000 levendgeborenen. De incidentie in de populatie 
van mola en GTN zijn geschat op respectievelijk 0,37 en 0,09 per 1.000 levendgeborenen. De 
gemiddelde leeftijd was 26,2 jaar. Gemiddelde pre-evacuatie hCG was 136.170 IE/l. De meeste 
gevallen werden gediagnosticeerd na abnormale echografische bevindingen (53,2%). De mate 
van progressie van CM en PM naar GTN was respectievelijk 24,2% en 8%, er was geen 
significant verschil tussen CM en PM met betrekking tot hCG-niveau, tijd tot hCG-normalisatie 
en progressiesnelheid naar GTN. 
 
Hoofdstuk 3, betreft een retrospectieve studie naar de uitkomst van verschillende 
behandelingsstrategieën bij patiënten met GTN van 40 jaar en ouder. We hebben de afgelopen 5 
jaar gegevens van 5 referentiecentra uit 5 landen (Egypte, Canada, Oekraïne, Saoedi -Arabië, en 
Indonesië) geanalyseerd. Medische dossiers van 118 vrouwen met GTN werden opgehaald, 
beoordeeld en geanalyseerd.  Demografische criteria en uitkomsten van verschillende 
behandelingsstrategieën werden geëvalueerd.  De gemiddelde leeftijd was 45,4 jaar. Van 80 
patiënten met Laag risico niet-gemetastaseerd GTN, werden 46 vrouwen behandeld met 
monochemotherapie. Bij 34 werd een hysterectomie met of zonder (n = 4) chemotherapie 
uitgevoerd. Deze behandeling was geassocieerd met een hoger remissiepercentage en een 
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kortere behandelingsduur (P=0,001). Bij 14 patiënten met laag risico gemetastaseerd GTN was 
het remissiepercentage 50% voor zowel Methotrexaat (MTX) alleen, als voor MTX plus 
hysterectomie. Twee van de 18 patiënten met een hoog risico stierven voordat de behandeling 
kon beginnen en één patiënt stierf tijdens de behandeling als gevolg van metastasen op afstand. 
Tien hoog risico casus ondergingen hysterectomie en chemotherapie als eerste lijn; 60% 
bereikte remissie. Wij concludeerden dat het hoogste remissiepercentage werd waargenomen in 
de niet-metastatische ziektegroep met een laag risico die werd behandeld met hysterectomie en 
de daaropvolgende 1-2 kuren. Een groot prospectief gerandomiseerde studie wordt aanbevolen 
om de waarde van de hysterectomie in de hoog risico groep en in de groep met laag risico en 
gemetastaseerde ziekte te onderzoeken, omdat is gebleken dat ook in deze groepen onverwachts 
vaak in de eerste behandellijn voor een hysterectomie wordt gekozen. 
 
Hoofdstuk 4 presenteert een gerandomiseerde gecontroleerde studie waarin een tweede 
curettage plus chemotherapie versus de chemotherapie alleen wordt vergeleken in vrouwen met 
persisterende trofoblast ziekte na een mola zwangerschap. We hebben 43 patiënten 
geanalyseerd in elke groep. De twee groepen waren vergelijkbaar wat betreft de 
basiskenmerken. De studie concludeerde dat er geen significant verschil was tussen de twee 
groepen met betrekking tot het aantal chemotherapiekuren, methotrexaat falen, complicaties van 
de chemotherapie, en de mate van terugval. Bovendien was alleen serum hCG gerelateerd aan 
het aantal chemotherapiekuren.  
 
Hoofdstuk 5, weerspiegelt een brief aan de redacteur waarin het belang van samenwerking in 
wetenschappelijk onderzoek tussen een Westers en niet- Westers land. Hierbij werden de lessen 
geleerd uit het in hoofdstuk 4 gepresenteerde onderzoek gedeeld. Wij schreven dat sommige 
ziekten zoals GTN en baarmoederhalskanker vaker voorkomen in de landen die over minder of 
onvoldoende middelen en infrastructuur beschikken om volgens de internationale richtlijnen 
studies correct uit te voeren. Andere voordelen van deze samenwerking werden besproken, 
zoals de lancering van de eerste trofoblast kliniek in Egypte, die nu dient als een 
referentiecentrum voor patiënten in de omgeving, en de ontwikkeling van een folder met 
patiëntinformatie in het Arabisch over molaire zwangerschap.  
 
In hoofdstuk 6, hebben we de verloskundige uitkomst van patiënten geëvalueerd die een 
vruchtbaarheid sparende behandeling hebben ondergaan voor gynaecologische premaligne en 
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kwaadaardige ziekten met inbegrip van GTN. De studie behelst het zwangerschapsverloop en 
bevallingsgegevens van 60 patiënten (inclusief 43 GTN-gevallen), die zwanger werden na een 
vruchtbaarheid sparende behandeling tussen januari 2012 en december 2015. We rapporteerden 
zwangerschapscomplicaties, afwijkingen tijdens de bevalling, neonatale uitkomst en het aantal 
zwangerschappen. De gemiddelde leeftijd was 24,9 jaar. De voorgaande diagnoses waren GTN 
(n = 43, 71,7%) en laag stadium ovariumcarcinoom (n = 14, 23,3%). Alle GTN-cases werden 
behandeld met chemotherapie. Drie casus met micro-invasief cervixcarcinoom of CIN III 
ondergingen een lis-excisie van de transformatie zone. Stadium 1a eierstokkanker werden 
behandeld met unilaterale salpingo-oophorectomie met peritoneale cytologie en biopsie van de 
andere eierstok. Vier vrouwen (6,7%) kregen een spontane miskraam. Bij 70,9% werd een 
keizersnede verricht, bij 20.5% werd daarbij verklevingen gezien. De neonatale uitkomst was in 
het merendeel normaal (n = 53), in 2 gevallen (3,6%) werden congenitale afwijkingen 
gevonden.  
 
In hoofdstuk 7 hebben we de prevalentie van GTD bestudeerd in de histologische preparaten 
van baarmoederevacuaties na een miskraam en post-abortieve bloedingen gepresenteerd aan de 
afdeling Pathologie van de Mansoura University Clinic en privépraktijken in de periode van 
1/1/2009 tot 31/3/2014.  
In totaal werden 600 miskraam curettage preparaten onderzocht. De gemiddelde leeftijd was 
26,5 jaar. De gemiddelde zwangerschapsduur was 10,3 weken. De meest voorkomende 
klinische diagnose van de verwezen gevallen was gemiste abortus (51,4%). Mola zwangerschap 
werd gediagnosticeerd in 103 van de 499 als miskraam verwezen casus (20,6%). 
Histopathologisch onderzoek na post-abortieve bloeding onthulde GTN in 12 van de 27 
gevallen (44,4%). Wij adviseren routinematig histopathologisch onderzoek van de 
baarmoederinhoud na curettage in de zwangerschap en post-abortieve bloeding.  
 
In hoofdstuk 8 werd de expressie van p57Kip2 in vroege molaire zwangerschappen en hun 
relatie tot de progressie naar GTN bestudeerd. Vijfenzestig histologische preparaten van 
conceptieproducten werden klinisch en pathologisch beoordeeld, en elke progressie  naar GTN, 
werd genoteerd. Pathologische beoordeling van het archiefmateriaal omvatte opnieuw gesneden 
secties van 5 μm dik, routinekleuring met hematoxyline en eosine en immunohistochemische 
kleuring van p57Kip2. Bepaalde histopathologische criteria bleken significant te zijn in 
differentiaties tussen complete hydatidiforme molazwangerschap en partiele hydatidiforme 
molazwangerschap, waaronder een villeuze vorm, villeus trofoblastische hyperplasie en atypie 
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in extravilleuse trofoblast. Er waren geen significante verschillen in morfologische of 
immunohistochemische kenmerken tussen gevallen die zich wel of niet ontwikkelde tot GTN. 
We concludeerden na deze studie dat p57Kip2-immunohistochemie van grote waarde is bij de 
diagnose in geval van een niet goed te duiden morfologie. Er waren echter geen specifieke 
kenmerken die de ontwikkeling tot GTN voorspelden.  
In hoofdstuk 9, we rapporteerden een geval van FRHM uit Egypte met een geschiedenis van 6 
terugkerende complete mola’s. Sequencing van het NLPR7-gen onthulde een schadelijke 
homozygote baseverandering in exon 2, c.197G> A, wat zou resulteren in een afgeknot eiwit 
p.W66*. Voor zover wij weten, werd deze mutatie nog niet eerder beschreven. 
 
Hoofdstuk 10 bespreekt de bevindingen van de gepresenteerde studies, hun impact op de 
klinische praktijk en toekomstperspectieven. 
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1. Avoid making a mountain out of an invasive hydatidiform mole: do a pregnancy test! A 
case report. 
 Published as: R Hemida, HC van Doorn. Avoid making a mountain out of an invasive hydatidiform mole: 
do a pregnancy test! The Lancet 2019; 394 (10194), e2. 
 
Case report. 
A 28 years old female patient was referred to the Trophoblastic Clinic of our hospital after her 
postoperative histopathology following hysterectomy revealed an “invasive mole”. The patient had 
normal menstrual cycles of 30 days with 5 days bleeding, but at the age of 26 years, her bleeding 
became irregular, prolonged and much heavier lasting 15-20 days with no prior missed periods. The 
patient had no history of contraception, hormonal therapy, or other medications. After three months 
of irregular bleeding, the patient visited her local gynaecologist who reported no definite uterine or 
cervical lesions and prescribed non-specific haemostatics. The patient’s hemoglobin was10 gm/dl 
but, neither urine nor serum hCG was checked.  
 For continuous bleeding problems, the patient underwent dilatation and curettage of uterus with 
endometrial biopsy that revealed “disordered proliferative endometrium”. The patient was advised 
to receive combined oral contraceptive pills that only decreased the uterine bleeding. Six month 
later, a repeated transvaginal ultrasound scan revealed focal anterior myometrial thickening with 
increased Doppler activity and the lesion was interpreted as “adenomyosis” (figure). Hysteroscopic 
endometrial resection was advised but severe bleeding occurred during the procedure and was 
stopped. Thereafter, profound bleeding persisted, her general condition deteriorated, and 
haemoglobin dropped to 6 gm/dl. After stabilizing with blood transfusion, a life-saving 
uncomplicated abdominal hysterectomy was performed. Histopathological examination of uterus 
revealed invasive mole without evidence of uterine perforation. Serum hCG was 550 IU/L and she 
was diagnosed with low-risk gestational trophoblastic neoplasia. Remission occurred after 2 courses 
of methotrexate. 
The cause of persistent uterine bleeding was not suspected as ultrasound image might be similar to 
that of other lesions as adenomyosis. Endometrial biopsy did not detect the lesion which existed in 
the deep myometrium. This case scenario shows that hCG test should not be neglected during initial 
assessment of abnormal uterine bleeding, as a trophoblastic tumour is easily cured often with single 
agent methotrexate without the need to perform a hysterectomy. 
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Figure: (A): Transvaginal ultrasound, E: endometrium. L: lesion; a focal heterogeneous area of 
anterior myometrium 3x2 cm. (B): Colour Doppler shows increased flow.  
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12.2 Patient information leaflet in Arabic: 
 
Diagram of uterus containing a complete 
mole 
Ultrasound picture of complete 
mole 
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12.3 PhD PORTFOLIO 
Name of PhD Student: Reda Hemida 
Erasmus MC Department : Gynecologic Oncology 
PhD Period:                            November 2012 - February 2019 
Promotor:                               Prof. dr. Curt W Burger 
Co-promotor: Dr. Helena C van Doorn 
.   
Training Courses and Workshops                                                                                        
  Year     ECT  
A. General courses. 
1. Research Ethics Online Training course, designed and produced by the 
World Health Organization (WHO).                                                              
2017       0.5            
 
 
2. 5th International Training Course of Scientific Writing and Publication. 
Mansoura Urology and Nephrology Center. Mansoura, Egypt.                                                                            
2014       1.0  
3. Design and Review of scientific research. Mansoura University 
Development Center.   
2016       0.4                                                                                                                                                                                                        
4. Statistical Analysis Skills.  Mansoura University Development Center, 
Mansoura. 
5. Design and preparation of electronic tests, Mansoura University                                      
Development Center                                                                                
2016      0.4 
 
2016     0.4 
 
6. Springer Journal Author Academy online course: "Writing Your 
Manuscript" www.Academy.Springer.com.                                                                                                
2015     0.3  
7. Education program of American College of Obstetrics and Gynecology 
"ACOG clinical perspectives in Obstetrics and Gynecology". 
2015     2.0  
B. Specific training courses in Gynecologic Oncology: 
1-Training in Gynecologic Oncology unit, Erasmus MC, Rotterdam, The 
Netherlands: (4 weeks) 
2012   6.0  
2- Masterclass in Gynecologic Oncology, Madrid-Spain. 2014   0.5  
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3- The Gynecologic Oncology and Surface Malignancy Workshop. Mansoura 
Oncology Center. Mansoura. 
2017   0.5  
Organizing training courses in Gynecologic Oncology: 
1- The 1st, 2nd, and 3rd courses of “Early detection of Gynecologic cancers. 
Mansoura University- Egypt .  (0.5 X 6)                                                                                                                    
2013-2018         
3.0 
 
2 – The First ESGO endorsed Gynecologic Oncology Workshop in Mansoura, 
Egypt.    
2015  0.5  
3- The 1st workshop on Gestational trophoblastic tumors: Diagnosis, treatment, 
and follow up. Faculty of Medicine, Mansoura University.                                                                
2017  0.4  
4-The 2nd international workshop in collaboration with ISSTD: Updates in 
management of trophoblastic tumors, Mansoura University.                                                                    
2018   0.4 
 
 
Attended Conferences 
-A speaker in an international conferences: 
1.  XIX World Congress of Gestational Trophoblastic diseases,                                       
Amsterdam, the Netherlands. 
2017   2.0   
2. 10th Breast and Gynecologic Immunotherapy Cancer Conference (BGICC)    
Cairo-Egypt. 
2018   2.0  
  3. 11th Breast and Gynecologic Immunotherapy Cancer Conference (BGICC)           2019   2.0  
-Poster presentation in an international conference: (5) 
18th ESGO meeting, Liverpool, UK  
19th ESGO meeting, Nice, France 
ESGO state-of-art meeting, Antalya, Turkey                                                  
20th ESGO meeting, Vienna, Austria  
21th ESGO meeting, Athens, Greece (2 abstracts)                                                           
 
2013  1.0 
2015  1.0 
2016  1.0 
2017  1.0 
2019   1.0 
 
-A speaker in a national conference:                                         
1.  The Annual conference of The Egyptian Society of Gynecologic Oncology 
(EGCS), Cairo 
2014    1.0  
2. The first Gynecologic Oncology Forum” of Mansoura University-Egypt. 
Mansoura and Sharm -Elsheikh, February 
2014     1.0  
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3. The 8th annual conference of “The Annual conferences of Department of 
Obstetrics and Gynecology, Sohag University. Hurghada 
2014.    1.0  
4. The 8th annual conference of Department of Obstetrics and Gynecology, 
Suez Canal University 
2015     1.0  
5. The 9th annual conference of Department of Obstetrics and Gynecology, 
Sohag University 
2016     1.0    
6. The first Gynecologic Oncology meeting, Zagazig University   2017     1.0  
7. The annual conference of The Egyptian Society of Gynecologic Oncology 
(EGCS)  
2017      1.0  
Attended meetings. 
Weekly tumor board meetings, department of Clinical Oncology  2014-2019 3.0  
First, 2nd, and 3rd GO meetings, Mansoura Oncology center  2016-2018 1.5  
Teaching activities: 
1. Undergraduate teaching, Faculty of Medicine, Mansoura University 
(Lectures-Clinical training-Assessment)  
2012-2019 3.0  
2. Course coordinator of Gynecologic Oncology. Mansoura-Manchester 
Program of Medical Education, Mansoura University 
 2015-2019 2.0  
3. Postgraduate teaching (Gynecologic Oncology) to Master and Doctorate 
degree students. Mansoura Faculty of Medicine 
 201- 2019 2.0  
4. Postgraduate teaching (Pelvic Anatomy) to Master degree students. 
Mansoura Faculty of Nursing 
2015- 2019 1.0  
Journal Editorial board membership. 
 World Journal of Clinical Case Conference (www.wjgnet.com).  2015-2018 1.0  
Advances in Modern Oncology Research (www.advmodoncolres.com). 2015-2018 1.0  
Reviewer: 
1.The Lancet  (1 peer review)                                                                 2019    1.0 
2. International Journal of Cancer.(2 peer reviews)                        2019   1.0  
3. Journal of Pharmacology Research International. (1 peer review)                        2018   0.5  
4. Saudi Medical Journal. (1 peer review)                        2016   0.5  
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5. Middle East fertility Society Journal (2 peer reviews)  
6. BMJ Open (1 peer review)                                                                                       
2017   1.0 
2019  0.5 
 
Membership of organizations and societies. 
A board member of Institutional Review Board (IRB) of medical research 
ethics, Mansoura University.  
 2016 -2019   
International Society of Study of Trophoblastic Diseases (ISSTD); Officer for 
Egypt and North Africa  
2019    
Egyptian Gynecologic Cancer Society (EGCS). 2010-2019  
European society of Gynecologic Oncology (ESGO). 2009-2019  
International Gynecologic Cancer Society (IGCS).  2009-2017  
Egyptian Society of Obstetrics and Gynecology.  2006-2019  
Supervision of Master and Doctorate degree thesis: 
Master degree of Obstetrics and Gynecology (5) 2007-2019 2.5  
Master degree of Radiology   (1) 2017   0.5  
Master degree of Nursing (2) 2013-2018 1.0  
Doctorate degree of Obstetrics and Gynecology (2) 2014-2019 2.0  
Doctorate degree of Pathology (1) 2010-2014 0.5    
Publications.                                                                           (from 2012 to 2019)  
A- In peer-reviewed international journals (Number: 20)   
B- In peer-reviewed national journals (Number:  6).   
Others         
Initiation of Gynecologic Oncology Unit-Mansoura University          2012 
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